



In Vivo Ligands of MDA5 and RIG-I in Measles Virus-Infected Cells

Simon Runge^{1,9}, Konstantin M. J. Sparrer^{2,9}, Charlotte Lässig^{1,9}, Katharina Hembach¹, Alina Baum³, Adolfo García-Sastre⁴, Johannes Söding^{1,5}, Karl-Klaus Conzelmann², Karl-Peter Hopfner^{1,5,9,*}

1 Gene Center and Department of Biochemistry, Ludwig-Maximilians University Munich, Munich, Germany, **2** Max von Pettenkofer-Institute, Gene Center, Ludwig-Maximilians University Munich, Munich, Germany, **3** Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, United States of America, **4** Department of Microbiology, Department of Medicine, Division of Infectious Diseases and Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America, **5** Center for Integrated Protein Science Munich, Munich, Germany

Abstract

RIG-I-like receptors (RLRs: RIG-I, MDA5 and LGP2) play a major role in the innate immune response against viral infections and detect patterns on viral RNA molecules that are typically absent from host RNA. Upon RNA binding, RLRs trigger a complex downstream signaling cascade resulting in the expression of type I interferons and proinflammatory cytokines. In the past decade extensive efforts were made to elucidate the nature of putative RLR ligands. *In vitro* and transfection studies identified 5'-triphosphate containing blunt-ended double-strand RNAs as potent RIG-I inducers and these findings were confirmed by next-generation sequencing of RIG-I associated RNAs from virus-infected cells. The nature of RNA ligands of MDA5 is less clear. Several studies suggest that double-stranded RNAs are the preferred agonists for the protein. However, the exact nature of physiological MDA5 ligands from virus-infected cells needs to be elucidated. In this work, we combine a crosslinking technique with next-generation sequencing in order to shed light on MDA5-associated RNAs from human cells infected with measles virus. Our findings suggest that RIG-I and MDA5 associate with AU-rich RNA species originating from the mRNA of the measles virus L gene. Corresponding sequences are poorer activators of ATP-hydrolysis by MDA5 *in vitro*, suggesting that they result in more stable MDA5 filaments. These data provide a possible model of how AU-rich sequences could activate type I interferon signaling.

Citation: Runge S, Sparrer KMJ, Lässig C, Hembach K, Baum A, et al. (2014) *In Vivo* Ligands of MDA5 and RIG-I in Measles Virus-Infected Cells. *PLoS Pathog* 10(4): e1004081. doi:10.1371/journal.ppat.1004081

Editor: Karen L. Mossman, McMaster University, Canada

Received: September 18, 2013; **Accepted:** March 6, 2014; **Published:** April 17, 2014

Copyright: © 2014 Runge et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work is funded by grants from the German Research Council (Deutsche Forschungsgemeinschaft, DFG GRK1721) and the Excellence Initiative of the German Ministry of Education and Science (Center for Integrated Protein Science Munich, CIPSM) to KPH, the National Institutes of Health (NIH U19AI083025) to KPH and AGS, the Bavarian government (BioSysNet) to KPH and JS, the DFG SFB646 to JS and K-PH and the DFG GRK1202 to KPH, KKC, SR and KS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: hopfner@genzentrum.lmu.de

⁹ These authors contributed equally to this work.

Introduction

The retinoic acid inducible gene I (RIG-I)-like receptor (RLR) proteins are key players in innate immunity and act by recognizing viral RNA (vRNA) in the cytosol. The RLR family consists of the members retinoic acid inducible gene I (RIG-I), melanoma differentiation associated protein 5 (MDA5), and laboratory of genetics and physiology 2 (LGP2) [1–3]. *In vitro* studies have shown that RIG-I and MDA5 recognize the majority of viruses in a complementary manner. While many negative-strand RNA viruses like rabies and influenza viruses are predominantly sensed by RIG-I, picornaviruses are predominantly recognized by MDA5. The observed preferences are, however, unlikely to be exclusive and the exact role of LGP2 still needs to be investigated [4–9]. In case of MDA5, a minor contribution to recognition of measles, rabies, vesicular stomatitis and Sendai virus has been reported [10–13].

The RLR proteins belong to the DExD/H-box ATPases sharing a central ATP-dependent helicase domain and a C-terminal regulatory domain (RD) that is responsible for initial

RNA binding. In addition, RIG-I and MDA5 possess N-terminal tandem caspase activation and recruitment domains (CARDs) that are responsible for downstream signaling transduction [2,14,15]. Several crystal structures of RIG-I have shown that, in the absence of virus, the protein exists in an auto-inhibited state where the RD domain folds back to the CARDs, thereby shielding them from the cytosol. Upon viral infection and initial vRNA binding, the protein undergoes large conformational changes leading to the interaction with the mitochondrial associated signaling protein (MAVS) [16–19]. This leads to the activation of a downstream signaling cascade and finally to the induction of type I interferon (IFN) expression and the establishment of an anti-viral state. Although the exact nature of RLR ligands is not yet fully understood, several studies report that RIG-I preferentially binds to relatively short (between 25 to 1000–2000 bp) 5'-triphosphate double-stranded RNAs (5'-triphosphate dsRNA) like those of Sendai virus (SeV) defective interfering (DI) particles [20–23]. In contrast, MDA5 seems to have a preference for long (more than 1000–2000 bp) dsRNA stretches [24,25]. Upon binding to dsRNA, MDA5 is thought to cooperatively form polar helical filaments leading to association

Author Summary

RIG-I-like receptors (RLRs) are helicase-like molecules that detect cytosolic RNAs that are absent in the non-infected host. Upon binding to specific RNA patterns, RLRs elicit a signaling cascade that leads to host defense via the production of antiviral molecules. To understand how RLRs sense RNA, it is important to characterize the nature and origin of RLR-associated RNA from virus-infected cells. While it is well established that RIG-I binds 5'-triphosphate containing double-stranded RNA, the *in vivo* occurring ligand for MDA5 is poorly characterized. A major challenge in examining MDA5 agonists is the apparently transient interaction between the protein and its ligand. To improve the stability of interaction, we have used an approach to crosslink MDA5 to RNA in measles virus-infected cells. The virus-infected cells were treated with the photoactivatable nucleoside analog 4-thiouridine, which is incorporated in newly synthesized RNA. Upon 365 nm UV light exposure of living cells, a covalent linkage between the labeled RNA and the receptor protein is induced, resulting in a higher RNA recovery from RLR immunoprecipitates. Based on next generation sequencing, bioinformatics and *in vitro* approaches, we observed a correlation between the AU-composition of viral RNA and its ability to induce an MDA5-dependent immune response.

with MAVS and activation of the downstream signaling cascade [26–28].

Viruses have developed numerous strategies to evade the immune system. For instance, viruses of the paramyxovirus family (e.g. measles, parainfluenza, Sendai and Nipah viruses) encode V inhibitor proteins that specifically bind to MDA5 and LGP2, but not always to RIG-I [29–31]. By determining the structure of MDA5 in complex with parainfluenza virus V-protein, we previously showed that the viral protein unfolds the ATPase domain of MDA5. This leads to the disruption of the MDA5 ATP-hydrolysis site and prevents RNA bound MDA5 filament formation [32].

One of the remaining key questions in this field is how RLR proteins are able to distinguish between self and non-self RNA in the cytosol. Recently, several studies showed that 5'-triphosphate RNA is not the only RNA ligand for RIG-I. Specific poly U/C-rich regions within certain viral genomes seem to contribute to efficient recognition by the protein [33,34]. In case of MDA5, it is not known which features of vRNA are required in order to induce an immune response. Expression of subgenomic and subgenic RNA from parainfluenza virus 5 (PIV5) indicated that MDA5 recognizes a specific region within the L mRNA [35]. For picornaviruses, it is speculated that MDA5 binds to long dsRNA that represents replicative intermediates composed of the positive genome and the negative antigenome [36]. These studies were, however, based on *in vitro* transfection experiments and it has so far not been possible to isolate a natural RNA ligand for MDA5 directly from virus-infected cells.

In this study we combined different methods, including RNA-protein crosslinking and deep sequencing, to investigate *in vivo* RNA ligands for RLR proteins from virus-infected cells. Based on the crosslinking we were able to co-purify immunostimulatory RNA in a RIG-I and MDA5 dependent manner from measles virus (MeV)-infected cells. Deep sequencing and bioinformatics analysis revealed that RIG-I and MDA5 bind RNA of positive polarity originating from the L gene of the MeV genome. In addition, RIG-I binds to the 5' ends of genomic and antigenomic RNAs, which probably represent 5'-triphosphate RNA, and are

therefore not recognized by MDA5. Furthermore, we showed that RIG-I, but not MDA5, binds RNA of negative polarity, indicating that MDA5 does not efficiently recognize the MeV genome. Based on bioinformatics analysis, we observed a correlation between MDA5-enriched RNA sequences and the AU content and this was confirmed by *in vitro* transcription assays. In summary, we report the isolation of MDA5-associated RNA from virus-infected cells and the discovery of *in vivo* occurring activating viral RNA ligands for MDA5.

Results

4-thiouridine treatment and 365 nm UV light exposure lead to improved RLR-associated RNA recovery from virus-infected cells

Several *in vitro* studies showed that MDA5 preferably recognizes long dsRNA stretches [24,25]. However, it is still unclear if the protein has a preference for specific RNA sequences. The main reason for this may lie in the weak interaction between the protein and its ligand resulting in very poor RNA levels that co-purify from MDA5 immunoprecipitates. In order to address this problem, we established an RNA-protein crosslinking approach adapted from the PAR-CLIP (Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation) methodology [37]. With this approach, we intended to improve RNA recovery from RLR immunoprecipitates in the context of a viral infection. For validation of the method, we compared the crosslinking approach with a conventional pull-down technique previously used for the identification of SeV DI particles as potent RIG-I inducers [20]. We infected A549 human lung carcinoma cells with SeV at a high multiplicity of infection (MOI) in the presence of 4-thiouridine (4SU) and allowed infection to occur over 24 h. A part of the cells was then exposed to 365 nm UV light and endogenous RIG-I was immunopurified (Figure 1a). The recovered RNA was isolated and subjected to quantitative PCR (qPCR) analysis and immunoactivity experiments. The data indicate that treatment of cells with 4SU and exposure to 365 nm UV light lead to a reduction of immunostimulatory activity of RIG-I-associated RNA to 50% (Figure 1b). However, the results of qPCR analysis showed that the crosslinking approach yields a quantitatively improved RNA recovery, with an increase of 50% in SeV DI particles in comparison to the non-crosslinking approach (Figure 1c and d). Furthermore, we confirmed that treatment of cells with the photoreactive nucleoside does not affect cell viability or virus replication (data not shown). Taken together, our data indicate that the crosslinking technique is a promising tool to study *in vivo* occurring RNA ligands for RLR proteins.

Next, we validated the crosslinking approach on cells that were infected with a variety of viruses, including negative-stranded (–) RNA viruses (MeV [38] and rabies [39]) and positive-stranded (+) RNA viruses (Encephalomyocarditis virus (EMCV [40]) and Mengo virus [41]). In all cases, we infected A549 cells at an MOI of 1.0 in the presence of 4SU. Cells were crosslinked 24 h post infection (hpi) and RIG-I and MDA5 were immunopurified. The recovered RNA was subjected to immunoactivity experiments. Based on the data, we concluded that immunoactive RNA was co-purified in a RIG-I- and MDA5-dependent manner from MeV-infected cells. This induction was significant in comparison to the negative control (Figure 2). In the case of RIG-I-associated RNA, we obtained an immunostimulatory effect that was 2600-fold higher in comparison to the control. For MDA5, we observed an 800-fold induction. The data show that the approach yields RIG-I- and MDA5-specific immunoactive RNA from MeV-infected cells in a RIG-I- and MDA5-dependent manner.




Figure 1. Validation of crosslinking and immunoprecipitation of RLR/RNA complexes from 24 h virus-infected cells. **A:** Schematic representation of the experimental procedure for characterization of RLR-associated RNA molecules. **B:** Immunostimulatory activity of RNA from RIG-I and control (GFP) crosslinking samples in comparison to non-crosslinking immunoprecipitates. **C:** Western blot analysis of crosslinked and non-crosslinked RIG-I and control (GFP) pull-down experiments. **D:** Comparison of RNA recovery levels by quantitative PCR analysis of RIG-I-associated RNA from SeV-infected cells (n=3). n.d.=not detectable. doi:10.1371/journal.ppat.1004081.g001

Although we detected significant immunostimulatory activity for RLR-associated RNAs from MeV-infected cells, the experimental set up is currently unsuitable for the isolation of RLR RNA ligands from the other viruses (Figure S1). The reason for this may lie in the heterogeneity and the need for precise timing of viral replication cycles or in the efficiency of 4SU incorporation and crosslinking. Utilization of this technique for other viruses may require adjustment of parameters, such as the time points of 4SU addition, crosslinking and harvesting after infection.

Deep sequencing reveals regions within the measles virus genome recognized by RIG-I and MDA5

Based on the above-mentioned results, we focused our studies on MeV, which belongs to the order of *Paramyxoviridae*. MeV has a single-stranded RNA genome of negative polarity consisting of

15,894 nucleotides. It comprises six non-overlapping genes, which are flanked by small terminal non-coding regions known as leader (*le*) and trailer (*tr*) sequences. These sequences serve as promoter regions during viral replication and transcription [42,43]. While the replication of the genome and antigenome is performed in a continuous manner, viral transcription is carried out in a sequential manner, giving rise to an mRNA gradient declining in the 3' to 5' direction (Figure S2), as previously published [44]. Since (–) RNA virus polymerases eventually fail in transcription termination, they generate, in addition to monocistronic mRNAs, numerous alternative RNA species including read-through transcripts, such as leader-N, bi- or tricistronic mRNAs [45]. Furthermore, replication can give rise to abortive replication products and DI RNA with large internal deletions or copy-back genomes [46]. Due to the complex RNA composition of




Figure 2. Immunoprecipitation of RLR-associated RNA from 24 h MeV infections. Validation of immunostimulatory activity of RNA from RIG-I, MDA5, and GFP immunoprecipitates upon transfection into 293T ISRE-FF reporter cells ($n=3$, ** $P<0.01$). doi:10.1371/journal.ppat.1004081.g002

a virus-infected cell, the analysis of specific RNA ligands for RLR proteins is challenging.

In order to shed light on the exact nature of RIG-I and MDA5-associated RNAs derived from MeV-infected cells, we performed a deep sequencing analysis on isolated RNA species from co-immunoprecipitations with antibodies against endogenous RIG-I and MDA5. As a control, we used an antibody against GFP (GFP protein was not present). The MeV strain used for the studies presented here was a recombinant measles virus rescued from cDNA with the exact sequence of the Schwarz vaccine strain (Genbank AF266291.1) [38].

Obtained sequences were mapped to the MeV antigenome and the relative abundances of these sequences between RIG-I pull-down, MDA5 pull-down, and GFP pull-down were compared. Analysis of the reads showed that RIG-I and MDA5 bind to similar regions within the L gene-derived RNAs. In addition, RIG-I, but not MDA5, binds to RNAs derived from the 3' and the 5' ends of the MeV genome (Figure 3a and b). These regions probably represent *le* or *tr*RNA generated in the course of replication or transcription. Additionally, internal genomic and antigenomic sequences found in the pull-downs could potentially originate from MeV DI particles [46–51]. To address this question, we performed a PCR analysis of RLR libraries in which we specifically amplified copyback DI RNA of MeV [47–49]. Indeed, we detected copyback DI particles not only in the RIG-I pull-down but also within RNA recovered from MDA5 immunoprecipitates (Figure S3). We did not find DIs in the GFP control pull-downs.

Consistent with previous work, the higher copy numbers of reads indicate that RIG-I binds MeV RNA with higher affinity than MDA5 [11]. This observation is in good agreement with the increased immunostimulatory activity of isolated RNA from RIG-I pull-down samples in comparison to MDA5. Regarding the immunostimulatory activity, RIG-I-associated RNA gives a 4-fold higher induction in comparison to MDA5-associated RNA (Figure 3d and e).

Analysis of deep sequencing data reveals remarkable differences in the strand-specificity of RIG-I and MDA5

Based on the protocol used for cDNA library preparation, sequencing reads could be separated according to their strand orientation. During cDNA synthesis, adaptors were specifically ligated to the 3' or 5' ends, thereby keeping the information of strand specificity during the deep sequencing run. Separation of sequences revealed remarkable differences between both protein immunoprecipitations. RIG-I associated RNA sequences of positive polarity, which represent either antigenomic RNA or mRNA transcripts, are enriched in regions close to the 5' end of the viral antigenome (leader) but also in distinct regions within the L gene. In contrast, sequences of negative polarity, representing the viral genome, are exclusively enriched in the 5' end of the genome (trailer region) and in regions of the L gene (Figure 4a).

Analysis of MDA5-associated RNA revealed that sequences of positive polarity were enriched within the L gene originating from similar regions as (+) RNA from the RIG-I library (Figure 4b). In contrast to RIG-I, however, MDA5 did not bind to RNA sequences comprising the 5' end of the antigenome or leader RNA. Comparison of (–) RNA from RIG-I and MDA5 libraries further revealed that, in contrast to RIG-I, MDA5 did not enrich sequences of negative polarity, including trailer sequences.

According to the analysis of strand specific enrichment, it appears that MDA5 does not bind vRNA of negative polarity that represents the MeV genome. Furthermore, the data evidently rule out the possibility that MDA5 recognizes RNA duplexes of (+) and (–) RNA that might represent replication intermediates, as previously suggested for a positive-strand RNA virus [36]. In fact, the result suggests that MDA5 binds (+) RNA that could either represent mRNA or the MeV antigenome.

To further validate the specificity of the accumulation of RIG-I and MDA5-associated RNA, we calculated specific read enrichments [52] of the RLR libraries compared to the control library (Figure S4). Enrichment (greater than 2× compared to the control library) of RIG-I-associated RNA of positive polarity can be found across the whole genome, whereas only few reads of negative polarity are enriched within the N and L segment. In contrast, enriched sequences of MDA5-associated RNA are exclusively present within the L segment of positive polarity, whereas no specific enrichment was observed for (–) RNA.

Based on the data, we observed a good correlation between the deep sequencing analysis and enrichment calculations, indicating that distinct regions within the MeV genome are indeed specifically enriched in a RIG-I- and MDA5-dependent manner in comparison to the control.

Confirmation of deep sequencing data with quantitative PCR

To independently validate the relative amount of RLR-associated RNA, qPCR amplification was performed. The obtained copy read numbers were normalized to the GFP negative control in order to compare the genomic segments in the RIG-I and MDA5 samples (Figure 5a). Analysis of relative abundances confirmed that RIG-I specifically enriches sequences from the 3' and 5' regions of the MeV genome, representing either antigenome or viral mRNA. Interestingly, the analysis showed that RIG-I-associated RNA from the genomic 3' end most likely represents leader read-through transcripts or abortive replication products and not N mRNA. In MDA5 pull-downs, RNA was enriched in the case of the L mRNAs and partly in the case of H mRNAs, while no relevant copy numbers were obtained at other genomic positions. This is in good agreement with the results of




Figure 3. Deep sequencing analysis of RLR-associated RNA from MeV-infected cells. **A–C:** RNA from RIG-I pull-down (red), MDA5 pull-down (blue), and control (GFP) pull-down (black) from MeV-infected cells were subjected to Illumina deep sequencing analysis. Obtained sequencing reads are mapped to their position on the viral antigenome. The x-axis corresponds to all possible 15,894 positions in the MeV antigenome and the y-axis shows the number of reads at the respective position. (A) RIG-I-associated sequences in comparison to the control mapped to the viral antigenome. (B) MDA5-associated sequences in comparison to the control mapped to the viral antigenome. (C) Overlay of RIG-I associated and MDA5-associated sequences. **D:** Western blot analysis of RIG-I and MDA5 immunoprecipitation in comparison to the GFP pull-down. **E:** Validation of immunostimulatory activity of RNA from RIG-I, MDA5, and GFP immunoprecipitates upon transfection into 293T ISRE-FF reporter cells. doi:10.1371/journal.ppat.1004081.g003




Figure 4. Strand separation of sequencing libraries into (+) and (-) MeV RNA. RNA deep sequencing libraries were generated based on the strand-specific mRNA sample preparation protocol from Epicentre. The Epicentre protocol encompasses sequential ligation of 5' and 3' adapters to RNA molecules, thus preserving strandness information. **A:** RIG-I-associated sequences in comparison to the control mapped to the viral antigenome. (+) RNA is shown in red; (-) RNA is shown in magenta; the control library is shown in black and grey. **B:** MDA5-associated sequences in comparison to the control mapped to the viral antigenome. (+) RNA is shown in blue, (-) RNA is shown in cyan; the control library is shown in black and grey. doi:10.1371/journal.ppat.1004081.g004

the deep sequencing analysis, indicating that MDA5 indeed recognizes RNA originating from the L gene of the MeV genome. Furthermore, comparison of the relative copy numbers between RIG-I and MDA5 revealed remarkable differences between both proteins. The relative abundances in the RIG-I sample were up to 40-fold higher in comparison to MDA5. This observation again indicates that RIG-I has a higher affinity for MeV RNA sequences in comparison to MDA5. Our conclusion is further supported by immunoactivity experiments, where the relative immunostimulatory activity of RIG-I-associated RNA was 20-fold higher in comparison to MDA5 (**Figure 5b and c**).

Bioinformatics analysis reveals a preferred binding of RIG-I and MDA5 to RNA species with a higher AU composition

To elucidate the exact nature of sequences enriched by RIG-I and MDA5 immunoprecipitations, we conducted a bioinformatics analysis. For this, the complete genome was divided into fragments of size 201 nt with a shifting window of 5 nt. Each sequence was folded *in silico* (RNAfold [53]) and several RNA primary and

secondary structure features were analyzed. The analyzed parameters were set in relation to the mean coverage of sequencing reads from RIG-I and MDA5 pull-down experiments. Heat scatter plots indicate that sequences rich in AU correlate with a high mean coverage of sequencing reads in both the RIG-I ($cor = 0.273$, $cor = 0.334$) and MDA5 ($cor = 0.358$, $cor = 0.348$) libraries (**Figure 6a and b**). These data suggest that RIG-I and MDA5 preferably bind to AU-rich sequences originating from the viral genome. Although we further analyzed a variety of secondary structure parameters, including paired nucleotides and bulges, we did not see any other relevant correlation with the mean coverage of sequencing reads (**Figure S5 and Figure S6**).

Confirmation of deep sequencing analysis by immunoactive experiments on *in vitro* transcripts

To further confirm the obtained sequencing data, we generated 17 single-stranded, 200 nucleotide long *in vitro* transcripts (IVTs) covering different regions of the MeV antigenome (**Table S1**). RNAs were double-phosphorylated in order to ensure that 5'-triphosphate groups were removed. For immunoactivity




Figure 5. Quantitative PCR analysis of RLR-associated RNA from MeV-infected cells. **A:** Comparison of RNA levels between RIG-I and MDA5 immunoprecipitates for each genomic segment at 24 hpi. Relative RNA ratios were normalized against the control (GFP) library (mean values, n = 2). **B:** Western blot analysis of RLR pull-down experiments in comparison to the GFP pull-down. **C:** Immunostimulatory activity of RLR-associated RNA at 24 hpi. doi:10.1371/journal.ppat.1004081.g005




Figure 6. Heatscatter plots of AU content of 201 nucleotide MeV RNA fragments and the fragment's mean coverage. The linear correlation is expressed via the Pearson coefficient. Every dot corresponds to one fragment with its respective AU content and mean coverage within an RLR library. The more yellow the plot, the more data points overlap. **A:** Correlation between AU composition and coverage of RIG-I-associated RNA of positive and negative RNA respectively. **B:** Correlation between AU composition and coverage of MDA5-associated RNA of positive and negative RNA respectively. doi:10.1371/journal.ppat.1004081.g006

experiments IVTs were transfected into 293T ISRE-FF reporter cells. The stimulatory effect revealed a correlation of high read numbers from deep sequencing analysis and high stimulatory activity of the IVT sequences (Figure 7). According to the immunostimulatory experiment, we observed increased immunostimulatory activities for transcripts 8, 9, and 12 (Figure 7a). These transcripts correspond to regions at the 5' end of the L gene, which is also the region with the highest copy numbers of reads (Figure 3). In general, IVTs representing regions within the L gene have higher immunostimulatory activity in comparison to the upstream genomic segments. This is in good agreement to the deep sequencing analysis. Furthermore, calculated Pearson correlations showed that the best correlation between maximal numbers of sequencing reads and the immunostimulatory activity of RNA transcripts can be found in the MDA5 sequencing data ($\text{cor} = 0.526$), while RIG-I and GFP samples showed less correlation ($\text{cor} = 0.369$ and $\text{cor} = 0.217$) (Figure 7b). In order to find a possible explanation for the different immunostimulatory potentials of IVTs, several characteristics of the transcripts were analyzed *in silico*. The obtained data revealed that the immunostimulatory potential correlates with the AU content of IVTs ($\text{cor} = 0.599$) (Figure 7d), which is consistent with the results from the deep sequencing analysis. Visualization of transcripts on an Agilent bioanalyzer RNA chip indicates that no higher-order structures due to the sequence composition were formed that might explain differences in immunostimulatory activity (data not shown).

In order to get a more general conclusion about the contribution of the AU content to the immunostimulatory potential of RNAs, *in vitro* transcripts from Mengo virus (Table S3) were tested for their immunostimulatory activity. The transcripts were generated according to the protocol for MeV RNA sequences. We again observed a correlation ($\text{cor} = 0.583$) of the AU content of the tested sequences and their immunostimulatory potential (Figure S 7a and b). These data are consistent with the *in vitro* analysis of MeV RNA sequences indicating that the AU composition of RNA might play a general role in activating RLR signaling.

In vitro transcripts with a low proportion of AU strongly stimulate ATP hydrolysis by MDA5

Finally, we asked whether the ATP hydrolysis activity of MDA5 correlates with the immunostimulatory potential of the tested IVTs. We measured the ATP hydrolysis rate of recombinant mouse MDA5 in the presence of RNA transcripts (Figure 7 and Figure S8) and observed a negative correlation between the maximum number of sequencing reads in the MDA5 library and the ATP hydrolysis rate ($\text{cor} = -0.414$, Figure 7c). Analysis of the *in vitro* data revealed that AU-rich sequences lead to a decrease in ATP hydrolysis activity of MDA5 ($\text{cor} = -0.445$). Furthermore, the ATP hydrolysis rate negatively correlates with the immunostimulatory potential of RNA transcripts ($\text{cor} = -0.426$) (Figure 7d). This result suggests that the ATPase hydrolysis activity of MDA5 is not correlated to the binding and the immunostimulatory potential of the RNA transcripts and could therefore provide a model of RNA recognition by the protein. The data are consistent with previous work on MDA5 filament formation upon dsRNA binding [26,27]. In structural and biophysical studies, Berke *et al* showed that ATP hydrolysis by MDA5 causes filaments to disassemble, perhaps by inducing translocation along the RNA or triggering a conformational change in the protein. According to our data, this may explain the observed inverse correlation between the immunostimulatory

activity of IVTs and their potential to induce the ATPase activity of MDA5.

Discussion

Until now, *in vivo* RLR ligands were poorly understood and a naturally occurring MDA5 ligand could only be purified indirectly by immunoprecipitation of LGP2:RNA complexes from virus-infected cells overexpressing LGP2 [54]. By applying a combination of RNA-protein crosslinking, immunoprecipitation of endogenous proteins and RNA deep sequencing analysis, we were able to investigate RLR-associated RNA from MeV infected cells. We compared our results to the empty GFP antibody control resembling a previously published immunoprecipitation strategy [20].

Our approach reveals that MDA5 preferentially binds measles virus RNA of positive polarity, whereas RIG-I additionally binds to (–) sense RNA within the trailer region as well as in the adjacent L gene. We propose that enriched RNA of positive polarity most likely represents mRNA species, since antigenomic RNA is only generated during replication and is immediately packed into nucleocapsids [55–57]. For *Mononegavirales*, these RNA-protein complexes are considered inaccessible for cytoplasmic proteins [55,58] and might not be ligands for RLR proteins unless they become released. We show that, unlike MDA5, RIG-I binds (+) sense RNA originating from not only the L genomic segment, but also from the 3' end of the MeV genome, which could be either *le*-N read-through transcripts or abortive replication products comprising 5'-triphosphate ends [45,46]. Furthermore, we hypothesize that RIG-I specific enriched RNA of negative polarity represents abortive replication products also having 5'-triphosphate ends [20–23]. Additionally, 5'-copyback DI sequences combining vRNA of positive and negative polarity were found both in RIG-I and MDA5 immunoprecipitates and may contribute to recognition [49].

Bioinformatics analysis and *in vitro* transcription experiments revealed a correlation between AU content and read coverage of the obtained sequences or IVTs, respectively. As shown before [59], this indicates that RNA rich in AU could serve as a putative ligand for RIG-I and MDA5, or in a secondary manner lead to a specific structure that is recognized by both proteins. The slightly weaker correlation of RIG-I associated sequences with their AU content compared to MDA5 bound RNAs could be explained by additional sequences or triphosphate RNAs recognized by RIG-I that originate from regions less rich in AU.

Interestingly, ATP hydrolysis assays performed with recombinant MDA5 and RNA transcripts indicate that the AU content of RNA negatively correlates with the ATP hydrolysis rate of the protein. This inverse correlation between the immunostimulatory potential of RNAs and their capability to stimulate ATP hydrolysis by MDA5 lets us speculate that the ATPase activity might not be necessary for, or even interfere with, the immunoactivity of RNA ligands. Although this observation disagrees with recent findings about the role of ATP hydrolysis in RIG-I oligomerization on 5'-triphosphate dsRNA [60], we assume that MDA5 and RIG-I differ markedly in their mechanical activation and the role of ATP hydrolysis. Our data is supported by results suggesting that MDA5 filament formation is abrogated in an ATP-sensitive manner. By electron microscopy (EM) analysis it was shown that MDA5 filaments disassemble in the presence of ATP, indicating that ATP hydrolysis triggers the translocation of the protein along the dsRNA molecule or reduces the binding affinity, thereby interfering with downstream signaling [26,27]. In light of the available data in the literature we therefore hypothesize that the




Figure 7. Analysis of *in vitro* transcribed RNA of the measles virus genome. Sequences were generated according to deep sequencing data. The transcripts were either transfected into 293T ISRE-FF reporter cells in order to validate the immunostimulatory potential or ATPase hydrolysis experiments were performed in presence of recombinant *mMDA5*. **A:** Comparison of relative luciferase activities (black) and relative ATPase activities (grey) of *in vitro* transcribed RNAs (n=3 and n=2 respectively, values were normalized to the highest mean value of each replicate). **B:** Pearson correlation between (+) RNA maximal coverage and relative luciferase activity. **C:** Pearson correlation between (+) RNA maximal coverage and relative ATPase activity. **D:** Correlation analysis between AU content and luciferase or ATPase activity, and between ATPase and luciferase activity. doi:10.1371/journal.ppat.1004081.g007

ATPase activity of the MDA5 helicase domain contributes to substrate specificity by detaching the protein from low affinity substrates. To further test this hypothesis we generated RIG-I^{E373Q} and MDA5^{E444Q}, which are mutated in the “Walker B” ATP hydrolysis motif [61], slowing down or abrogating the ATP hydrolysis activity of the proteins, while preserving formation of ATP complexes. Overexpression of these mutant proteins from transfected plasmids showed a dramatic increase in their immunostimulatory potential in the absence of any viral ligands in comparison to expressed wild-type MDA5 (Figure S9). Furthermore, pull-down studies with the RIG-I Walker B mutant revealed an increase in the amount of recovered RNA while their immunostimulatory potential decreased (data not shown). The increased immunostimulation of ATPase deficient RLRs is consistent with the model that RNAs that lead to a reduced ATP-hydrolysis rate are more proficient in immunostimulation, possibly by stabilizing RLR:RNA complexes. The negative correlation between AU-rich sequences and the ATP hydrolysis rate suggests that MDA5 binds AU-rich RNA in preference to GC-rich RNA. This would lead to a stronger interaction between RNA and MDA5 and result in a higher immunostimulatory signal. In order to test this hypothesis, we performed binding assays with MDA5 and IVTs but we were not able to demonstrate differences in the binding affinities between the different transcripts that might support this theory (data not shown). Finally, we speculate that RNA ligands for RLR proteins could be divided into two classes. The first class would comprise RNA molecules originating from the 5'-triphosphate ends of the genome or antigenome. These molecules could be generated in the course of read-through transcription and abortive replication [45,46] and could therefore represent preferred ligands of RIG-I, as shown previously [20]. The second class of RNA molecules could be recognized by both receptor proteins. Our data suggest that recognition of these RNAs might occur through the AU composition of sequences [34]. This second class might also prominently include defective interfering (DI) particles generated during MeV replication. For MDA5, however, our deep sequencing data show that the (-) strand portion of the DIs is either relatively short or the fraction of DIs binding to MDA5 is magnitudes lower than the binding to L derived (+) sense RNAs and therefore not easily detectable during sequencing. A more detailed analysis of the deep sequencing data is currently ongoing in order to shed more light on the complex nature of the DIs involved.

It will be interesting to see what types of RNA associate with RIG-I and MDA5 during infections with different viruses and to what extent the AU composition and DI generation contributes to RNA recognition in these types of viruses. In particular, the finding that both RIG-I and MDA5 localize to AU rich regions suggests partially overlapping roles in detection of different viruses. The specificity of RIG-I and MDA5 for certain viruses may lie not only in the detection of 5'-triphosphate by RIG-I, but also in the heterogeneity of viral evasion strategies [62]. Our findings support a model for the recognition of AU-rich sequences by RIG-I and MDA5 from MeV-infected cells. Consistently, we find a similar correlation for *in vitro* transcribed RNA from the Mengo virus genome.

In general, the data support previous experiments indicating that MeV is mainly recognized by RIG-I, while MDA5 seems to play a minor role [4,5,13,63]. It could be possible that RIG-I initially recognizes *le-N* read-through transcripts or abortive replication products containing 5'-triphosphate ends, leading to the activation of the signaling cascade. In a second round of recognition, RIG-I and MDA5 then recognize viral transcripts that are rich in AU. To further test this hypothesis, time dependent experiments need to be carried out.

One feature of the applied crosslinking technique is the introduction of specific T to C transitions at the interaction sites of 4SU-labeled RNA and the protein upon UV light exposure [37]. By identifying these point mutations in the deep sequencing data, one can exactly pinpoint the RNA sequences that interact with the protein of interest. However, our bioinformatics analysis did not reveal significant enrichment of T to C mutations, which could be explained by the rather low incorporation efficiency of the photoreactive nucleoside into viral RNA, consistent with the low incorporation level of 4SU into host RNA. Nevertheless, by increasing the incorporation efficiency in future studies, the identification of point mutants could further narrow down the precise binding sites of RLRs.

In summary, our approach provides a first insight into the molecular basis of vRNA derived from MeV interaction with MDA5 in living cells and reveals a preference for binding of AU-rich regions originated from (+)-sense RNA of the L gene. *In vitro*, these RNA molecules appear to be a poorer stimulator of the ATPase activity of MDA5, and result in more stable MDA5 filaments and support better downstream signaling.

Materials and Methods

Cell lines, viruses and antibodies

Infection experiments were carried out in A549 human lung carcinoma cells. HEK 293T ISRE-FF reporter cells (stable expression of firefly luciferase under the control of an interferon stimulated response element) were used for interferon stimulation luciferase reporter gene assays. All cells were maintained in Dulbecco's Modified Eagle Medium supplemented with 2 mM L-glutamine, 1% Penicillin-Streptomycin and 10% FBS (all purchased from Invitrogen). Viruses used for infections were recombinant measles virus with a sequence identical to the vaccine strain Schwarz (AF266291.1), Sendai virus, Sendai virus defective interfering particles H4 (kindly provided by Dominique Garcin, Geneva, Switzerland), Mengo virus strain pMC0 (kindly provided by Anne Krug, TU Munich, Germany) and EMCV. Primary antibodies to human MDA5 (AT113) and RIG-I (Alme-1) were purchased from Enzo Life Science (Loerrach, Germany). Antibody to GFP (ab1218) was obtained from Abcam (Cambridge, UK). Secondary antibodies were supplied by GE Healthcare (Buckinghamshire, UK).

Crosslinking and immunoprecipitation of RLR-associated RNA from virus-infected cells

A549 cells were infected with virus with an MOI of 1.0 in the presence of 400 μ M 4SU. Infection was allowed to proceed for 24 h and living cells were washed with PBS (10 mM phosphate, 137 mM NaCl, 2.7 mM KCl, pH 7.5) and exposed to 1 J/cm² 365 nm UV light using a photocrosslinker (Vilbert Lourmat). Cells were harvested and incubated in Nonidet P-40 lysis buffer (50 mM HEPES, 150 mM KCl, 1 mM NaF, 10 μ M ZnCl₂, 0.5% NP-40, 0.5 mM DTT, protease inhibitor, pH 7.5) for 10 min on ice. The lysate was cleared by centrifugation and endogenous proteins were immunoprecipitated for 4 h with the respective antibodies (1 μ g/mL) bound to protein G Dynabeads (Life Technologies). The beads were washed five times with high-salt wash buffer (50 mM HEPES, 500 mM KCl, 0.05% NP-40, 0.5 mM DTT, protease inhibitor, pH 7.5) and incubated with proteinase K (Thermo Scientific) for 30 min at 55°C. The RNA was isolated by phenol/chloroform/isoamylalcohol extraction and subjected to further analysis.

Total RNA isolation from virus infected cells

A549 cells were infected with MeV with an MOI of 1. Cells were harvested 24 hpi. Total RNA was isolated according to

manufacturer's protocol of the RNeasy Protect Mini Kit (Qiagen) and subjected to Illumina deep sequencing.

Luciferase transfection assay

Immunoactivity experiments were carried out in 24-well plates. 2.5×10^5 HEK 293T ISRE-FF reporter cells were transfected with 250 ng of recovered RNA, 500 ng *in vitro* transcripts or 500 ng plasmid DNA using Lipofectamine 2000 (Invitrogen) according to manufacturer's protocol. After 24 h incubation, cells were subjected to immunoactivity experiments using the Dual-Glo luciferase assay system (Promega) according to manufacturer's instructions. The luciferase activity was determined in a 96-well plate reader. Significance of differences in luciferase activity between samples were determined via an unpaired t-test.

cDNA library preparation and deep sequencing analysis

Isolated RNA was prepared for Illumina sequencing using the mRNA-Seq library preparation kit (Epicentre) according to manufacturer's protocol. To remove ribosomal RNA species from the sequencing libraries a Ribo-Zero rRNA removal kit (Epicentre) was used. Quality of RNA-Seq libraries was validated on a DNA1500 chip for the Bioanalyzer 2100 (Agilent). Sequencing was performed on the Illumina Genome Analyzer in the Gene Center sequencing facility (LAFUGA). Obtained sequences were processed with the FASTX toolkit (http://hannonlab.cshl.edu/fastx_toolkit/) in order to remove adapter sequences and reads with PHRED scores below 30. Remaining sequences were mapped to human and viral genomes by utilization of the Bowtie algorithm [64], allowing maximal one mismatch per unique read. The Bowtie sequence alignments were converted with SAMtools [65] to pileup format, which was subsequently used for further data analysis. Relative sequence abundances were analyzed between RLR pull-down samples and the GFP control. Specific read enrichments were calculated by determining the relative sequence abundance at each position on the genomic segment and calculating the average of the RLR/GFP ratios over a dynamic window of 200 reads. Relative sequence abundances with \log_2 ratios above +1 were defined as significantly enriched in the RLR library.

Analysis of RNA sequences

RNA secondary structure prediction from measles virus genome or *in vitro* transcripts was performed by utilization of RNAfold from the ViennaRNA package [53] using standard parameter settings. For this purpose, the genome was divided into 201 nt fragments with a shifting window size of 5 nt. The sequences were folded *in silico* and the linear relationship between different data sets was quantified with the Pearson correlation coefficient.

SYBR green quantitative PCR analysis

DNase treatment of the immunoprecipitated RNAs and qPCR was performed as previously described [66]. The primer pairs used for quantification were identical to those published [67]. For cDNA synthesis a random hexanucleotide mix was used (Roche). Full length MeV vac2 cDNA with a known concentration was used for standard generation. Copy number values obtained for MDA5 and RIG-I were normalized to the control GFP.

PCR for 5'-copyback defective interfering genome detection

Specific primers for reverse transcription (Roche transcriptase) and the subsequent PCR (Biozym Phusion Polymerase) were adapted from Calain et al [47]. PCR products were analyzed on agarose gels and stained with ethidium bromide.

T7 RNA transcription

Templates were generated for *in vitro* transcription in a PCR adding the T7 promoter sequence (TAATACGACTCACTATA GGG) to the 5' end of the desired MeV or Mengo virus genomic fragment, respectively (for oligonucleotides see **Tables S2 and S4** respectively). PCR products were subsequently purified on agarose gels. RNA was transcribed using the Ambion Megashortscript T7 Kit according to the manufacturer's protocols. The reaction was incubated overnight at 37°C and RNA was precipitated using LiCl at -20°C for 30 minutes. Afterwards, RNA was subjected to triphosphate digestion using FastAP (Fermentas) according to the manufacturer's instructions and purified on denaturing 8 M urea/10% polyacrylamide gels at 25 mA constant current. Gel slices containing RNA were incubated overnight with 450 μ L probe elution buffer (0.5 M ammonium acetate, 1 mM EDTA, 0.2% SDS). Eluted RNA was isolated by phenol/chloroform/isoamylalcohol extraction and precipitated with ethanol.

ATPase hydrolysis assays

ATPase hydrolysis activity was determined using [γ - P^{32}] ATP. Mouse MDA5 was purified as described previously [32] and 1.6 μ M of protein was preincubated with 80 nM *in vitro* transcribed RNA for 10 min at room temperature. The reaction was initiated by addition of ATPase hydrolysis buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 1.5 mM $MgCl_2$, and 2 mM DTT) containing 2 mM ATP and 0.2 μ Ci [γ - P^{32}] ATP. The hydrolysis rate was monitored over 1 h and analyzed by thin layer chromatography (TLC).

Generation of RLR mutants

Sequences encoding full-length human RIG-I with N-terminal FLAG-tag and full-length human MDA5 with N-terminal FLAG-tag were cloned into pcDNA5 FRT/TO (Invitrogen). Mutants (FLAG-RIG-I E373Q and FLAG-MDA5 E444Q) were generated by site directed mutagenesis with PfuUltra (Agilent).

Supporting Information

Figure S1 Validation of immunostimulatory activity of RNA from RIG-I, MDA5, and GFP immunoprecipitates upon transfection into 293T ISRE-FF reporter cells (n = 3, ** P<0.01). (TIF)

Figure S2 Deep sequencing analysis of total RNA from MeV-infected cells 24 hpi. RNA was isolated according to manufacturer's protocol of the RNeasy Protect Mini Kit (Qiagen) and total RNA was subjected to Illumina deep sequencing. The data show an mRNA gradient declining in the 5' to 3' direction, while RNA of negative polarity has no relevant copy numbers. (TIF)

Figure S3 Qualitative PCR analysis of MeV copyback DI RNA. Following a specific reverse transcription of RNA with a primer binding at the 3'-terminus of the antigenome, 5'-copyback DI genomes were specifically amplified using another primer in the same direction 600 nt downstream. The PCR was afterwards analyzed on agarose gels to separate the amplicons of specific copyback DIs with different length and branching points. The RNA used for these experiments is indicated on the lanes (RIG-I, MDA5 and GFP immunoprecipitates). (TIF)

Figure S4 Enrichments in RLR sequencing libraries. Binary logarithms of RLR to GFP ratios of sequence reads (\log_2 [read number RLR/read number GFP] * [total read number

GFP/total read number RLR)) were calculated in order to determine specific accumulations within the RLR libraries. Data points with \log_2 ratios above 1 represent sequencing reads that were enriched in comparison to the control (GFP) library. **A:** Enrichments within the whole RIG-I (+) or (-) stranded sequencing library. **B:** Enrichments within the whole MDA5 (+) or (-) stranded sequencing library. **C:** Similar to A and B, but zoomed in view of the enrichments for positive polarity (le)N and L segments. Mean values for RIG-I and MDA5 \log_2 ratios are shown in red and blue, respectively. Standard deviations are represented in grey. The mean coverage of (+) RNA sequences is shown for the RIG-I (red), MDA5 (blue), and GFP (black) libraries below each graph. (TIF)

Figure S5 Secondary structure analysis of several features from *in silico* folded 201 nucleotide MeV RNA fragments and correlation to the fragment's mean coverage within the RIG-I sequencing library. *In silico* folding was done with RNAfold using standard parameters. The analysis is visualized in heatscatter plots and the linear correlation is expressed via the Pearson coefficient. Every dot corresponds to one fragment with its depicted feature and mean coverage. The more yellow the plot, the more data points overlap. Analyzed RNA features are: number of paired nucleotides, longest paired stretch, number of stem-loops, mean size of stem-loops, number of bulges, mean size of bulges and mean number of paired nucleotides per branch. **A:** Correlation analysis of RNA secondary structure features with the RIG-I associated RNA of positive polarity. **B:** Correlation analysis of RNA secondary structure features with the RIG-I associated RNA of negative polarity. (TIF)

Figure S6 RNA secondary structure analysis of several features from *in silico* folded 201 nucleotide MeV RNA fragments and correlation to the fragment's mean coverage within the RIG-I sequencing library. Foldings were performed with RNAfold using standard parameters. The analysis is visualized in heatscatter plots and the linear correlation is expressed via the Pearson coefficient. Every dot corresponds to one fragment with its depicted feature and mean coverage. The more yellow the plot, the more data points overlap. Analyzed RNA features are: number of paired nucleotides, longest paired stretch, number of stem-loops, mean size of stem-loops, number of bulges, mean size of bulges and mean number of paired nucleotides per branch. **A:** Correlation analysis of RNA secondary structure features with the RIG-I associated RNA of positive polarity. **B:** Correlation analysis of RNA secondary structure features with the RIG-I associated RNA of negative polarity. (TIF)

Figure S7 Analysis of *in vitro* transcribed RNA of the Mengo virus genome. Six 201 nt fragments were chosen to include low and high AU content. Transcripts were transfected

into 293T ISRE-FF reporter cells in order to validate the immunostimulatory potential. **A:** Relative luciferase activity of transfected RNA (n = 3). **B:** Pearson correlation between (+) RNA maximal coverage and the relative luciferase activity. (TIF)

Figure S8 MDA5 ATPase activity assay. Free phosphate was separated by thin layer chromatography (TLC) and visualized on a Storm PhosphorImager from Molecular Dynamics. The ATPase hydrolysis rate was determined by quantifying free phosphate in comparison to non-hydrolyzed ATP 15 min after adding $[\gamma\text{-P}^{32}]$ ATP to the reaction mixture. (TIF)

Figure S9 Immunostimulatory activity of overexpressed Walker B mutants RIG-I^{E373Q} and MDA5^{E444Q} compared to wildtype proteins in 293T ISRE-FF reporter cells (n = 3, ** P<0.01, *** P<0.001). (TIF)

Table S1 Sequences of *in vitro* transcribed MeV RNAs. The gene annotation with the exact nucleotide position on the MeV genome is shown in brackets. (DOCX)

Table S2 Oligonucleotides used for generation of *in vitro* transcribed MeV sequences. (DOCX)

Table S3 Sequences of *in vitro* transcribed Mengo RNAs. The gene annotation with the exact nucleotide position on the Mengo virus genome is shown in brackets. (DOCX)

Table S4 Oligonucleotides used for generation of *in vitro* transcribed Mengo sequences. (DOCX)

Acknowledgments

We kindly thank Dr. Luis Martinez-Sorbido (University of Rochester, Rochester, NY) for the 293T ISRE-FF cell line, Dominique Garcin (University of Geneva, Switzerland) for providing SeV defective interfering particles H4 and Anne Krug (TU Munich, Germany) for providing Mengo virus, Manuela Moldt for purifying mMDA5, LAFUGA and especially Stefan Krebs for help with sequencing, Philipp Torkler and Alexander Graf for help with data analysis, Richard Cadagan and Osman Lizardo for technical assistance and Robert Byrne for critically reading our manuscript.

Author Contributions

Conceived and designed the experiments: SR KMJS CL. Performed the experiments: SR KMJS CL AB. Analyzed the data: SR CL KH. Contributed reagents/materials/analysis tools: KPH KKC AGS JS. Wrote the paper: SR KMJS CL KPH KKC AGS. Designed the bioinformatical tools used in analysis: KH JS.

References

1. Loo Y-M, Gale Jr M (2011) Immune signaling by RIG-I-like receptors. *Immunity* 34: 680–692.
2. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, et al. (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. *Nat Immunol* 5: 730–737.
3. Kato H, Takahashi K, Fujita T (2011) RIG-I-like receptors: cytoplasmic sensors for non-self RNA. *Immunol Rev* 243: 91–98.
4. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, et al. (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* 441: 101–105.
5. Loo Y-M, Formek J, Crochet N, Bajwa G, Perwitasari O, et al. (2008) Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. *J Virol* 82: 335–345.
6. Plumet S, Herschke F, Bourhis J-M, Valentin H, Longhi S, et al. (2007) Cytosolic 5'-triphosphate ended viral leader transcript of measles virus as activator of the RIG I-mediated interferon response. *PLoS One* 2: e279.
7. Saito T, Hirai R, Loo Y-M, Owen D, Johnson CL, et al. (2007) Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. *Proc Natl Acad Sci USA* 104: 582–587.
8. Satoh T, Kato H, Kumagai Y, Yoneyama M, Sato S, et al. (2010) LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. *Proc Natl Acad Sci USA* 107: 1512–1517.
9. Wilkins C, Gale M (2010) Recognition of viruses by cytoplasmic sensors. *Curr Opin Immunol* 22: 41–47.
10. Faul EJ, Wanjalla CN, Suthar MS, Gale Jr M, Wirblich C, et al. (2010) Rabies virus infection induces type I interferon production in an IPS-1 dependent

- manner while dendritic cell activation relies on IFNAR signaling. *PLoS Path* 6: e1001016.
11. Ikegane S, Takeda M, Ohno S, Nakatsu Y, Nakanishi Y, et al. (2010) Both RIG-I and MDA5 RNA helicases contribute to the induction of alpha/beta interferon in measles virus-infected human cells. *J Virol* 84: 372–379.
 12. Saito T, Gale Jr M (2007) Principles of intracellular viral recognition. *Curr Opin Immunol* 19: 17–23.
 13. Yount JS, Gitlin L, Moran TM, López CB (2008) MDA5 participates in the detection of paramyxovirus infection and is essential for the early activation of dendritic cells in response to Sendai virus defective interfering particles. *J Immunol* 180: 4910–4918.
 14. Fujita T, Onoguchi K, Onomoto K, Hirai R, Yoneyama M (2007) Triggering antiviral response by RIG-I-related RNA helicases. *Biochimie* 89: 754–760.
 15. Wang Y, Ludwig J, Schuberth C, Goldeck M, Schlee M, et al. (2010) Structural and functional insights into 5'-ppp RNA pattern recognition by the innate immune receptor RIG-I. *Nat Struct Mol Biol* 17: 781–787.
 16. Civril F, Bennett M, Moldt M, Deimling T, Witte G, et al. (2011) The RIG-I ATPase domain structure reveals insights into ATP-dependent antiviral signalling. *EMBO reports* 12: 1127–1134.
 17. Jiang F, Ramanathan A, Miller MT, Tang G-Q, Gale M, et al. (2011) Structural basis of RNA recognition and activation by innate immune receptor RIG-I. *Nature* 479: 423–427.
 18. Kowalinski E, Lunardi T, McCarthy AA, Loubser J, Brunel J, et al. (2011) Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. *Cell* 147: 423–435.
 19. Luo D, Ding SC, Vela A, Kohlway A, Lindenbach BD, et al. (2011) Structural insights into RNA recognition by RIG-I. *Cell* 147: 409–422.
 20. Baum A, Sachidanandam R, Garcia-Sastre A (2010) Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. *Proc Natl Acad Sci USA* 107: 16303–16308.
 21. Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, et al. (2006) 5'-Triphosphate RNA is the ligand for RIG-I. *Science* 314: 994–997.
 22. Pichlmair A, Schulz O, Tan CP, Näslund TI, Liljeström P, et al. (2006) RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. *Science* 314: 997–1001.
 23. Schlee M, Roth A, Hornung V, Hagmann CA, Wimmenauer V, et al. (2009) Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. *Immunity* 31: 25–34.
 24. Kato H, Takeuchi O, Mikamo-Sato E, Hirai R, Kawai T, et al. (2008) Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. *J Exp Med* 205: 1601–1610.
 25. Pichlmair A, Schulz O, Tan C-P, Rehwinkel J, Kato H, et al. (2009) Activation of MDA5 requires higher-order RNA structures generated during virus infection. *J Virol* 83: 10761–10769.
 26. Berke IC, Modis Y (2012) MDA5 cooperatively forms dimers and ATP-sensitive filaments upon binding double-stranded RNA. *EMBO J* 31: 1714–1726.
 27. Berke IC, Yu X, Modis Y, Egelman EH (2012) MDA5 assembles into a polar helical filament on dsRNA. *Proc Natl Acad Sci USA* 109: 18437–18441.
 28. Peisley A, Lin C, Wu B, Orme-Johnson M, Liu M, et al. (2011) Cooperative assembly and dynamic disassembly of MDA5 filaments for viral dsRNA recognition. *Proc Natl Acad Sci USA* 108: 21010–21015.
 29. Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, et al. (2004) The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN- β promoter. *Proc Natl Acad Sci USA* 101: 17264–17269.
 30. Childs K, Stock N, Ross C, Andrejeva J, Hilton L, et al. (2007) mda-5, but not RIG-I, is a common target for paramyxovirus V proteins. *Virology* 359: 190–200.
 31. Parisien J-P, Bamming D, Komuro A, Ramachandran A, Rodriguez JJ, et al. (2009) A Shared Interface Mediates Paramyxovirus Interference with Antiviral RNA Helicases MDA5 and LGP2. *J Virol* 83: 7252–7260.
 32. Motz C, Schuhmann KM, Kirchofer A, Moldt M, Witte G, et al. (2013) Paramyxovirus V proteins disrupt the fold of the RNA sensor MDA5 to inhibit antiviral signaling. *Science* 339: 690–693.
 33. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale Jr M (2008) Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. *Nature* 454: 523–527.
 34. Schnell G, Loo Y-M, Marcotrigiano J, Gale Jr M (2012) Uridine composition of the poly-U/UC tract of HCV RNA defines non-self recognition by RIG-I. *PLoS Path* 8: e1002839.
 35. Luthra P, Sun D, Silverman RH, He B (2011) Activation of IFN- β expression by a viral mRNA through RNase L and MDA5. *Proc Natl Acad Sci USA* 108: 2118–2123.
 36. Feng Q, Hato SV, Langereis MA, Zoll J, Virgen-Slane R, et al. (2012) MDA5 Detects the double-stranded RNA replicative form in picornavirus-infected cells. *Cell reports* 2: 1187–1196.
 37. Hafner M, Landthaler M, Burger L, Khorshid M, Haussler J, et al. (2010) Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. *Cell* 141: 129–141.
 38. del Valle JR, Devaux P, Hodge G, Wegner NJ, McChesney MB, et al. (2007) A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. *J Virol* 81: 10597–10605.
 39. Schnell MJ, Mebatsion T, Conzelmann K-K (1994) Infectious rabies viruses from cloned cDNA. *EMBO J* 13: 4195.
 40. Hoskins J, Sanders F (1957) Propagation of mouse encephalomyocarditis virus in ascites tumour cells maintained in vitro. *Br J Exp Pathol* 38: 268.
 41. Osorio JE, Martin LR, Palmenberg AC (1996) The immunogenic and pathogenic potential of short poly (C) tract Mengo viruses. *Virology* 223: 344–350.
 42. Colonna RJ, Banerjee AK (1976) A unique RNA species involved in initiation of vesicular stomatitis virus RNA transcription in vitro. *Cell* 8: 197–204.
 43. Leppert M, Rittenhouse L, Perrault J, Summers DF, Kolakofsky D (1979) Plus and minus strand leader RNAs in negative strand virus-infected cells. *Cell* 18: 735–747.
 44. Cattaneo R, Rebmann G, Schmid A, Baczkos K, Ter Meulen V, et al. (1987) Altered transcription of a defective measles virus genome derived from a diseased human brain. *EMBO J* 6: 681.
 45. Plumet S, Duprex WP, Gerlier D (2005) Dynamics of viral RNA synthesis during measles virus infection. *J Virol* 79: 6900–6908.
 46. Mottet G, Curran J, Roux L (1990) Intracellular stability of nonreplicating paramyxovirus nucleocapsids. *Virology* 176: 1–7.
 47. Calain P, Curran J, Kolakofsky D, Roux L (1992) Molecular cloning of natural paramyxovirus copy-back defective interfering RNAs and their expression from DNA. *Virology* 191: 62–71.
 48. Calain P, Roux L (1988) Generation of measles virus defective interfering particles and their presence in a preparation of attenuated live-virus vaccine. *J Virol* 62: 2859–2866.
 49. Pfaller CK, Radeke MJ, Cattaneo R, Samuel CE (2014) Measles Virus C Protein Impairs Production of Defective Copyback Double-Stranded Viral RNA and Activation of Protein Kinase R. *J Virol* 88: 456–468.
 50. Rima B, Davidson W, Martin S (1977) The role of defective interfering particles in persistent infection of Vero cells by measles virus. *J Gen Virol* 35: 89–97.
 51. Whistler T, Bellini WJ, Rota P (1996) Generation of defective interfering particles by two vaccine strains of measles virus. *Virology* 220: 480–484.
 52. Wood HM, Belvedere O, Conway C, Daly C, Chalkley R, et al. (2010) Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens. *Nucleic Acids Res* 38: e151–e151.
 53. Lorenz R, Bernhart SH, Zu Siederdisen CH, Tafer H, Flamm C, et al. (2011) ViennaRNA Package 2.0. *Algorithms Mol Biol* 6: 26.
 54. Deddouche S, Goubau D, Rehwinkel J, Chakravarty P, Begum S, et al. (2014) Identification of an LGP2-associated MDA5 agonist in picornavirus-infected cells. *eLife* 3: e01535.
 55. Blumberg BM, Leppert M, Kolakofsky D (1981) Interaction of VSV leader RNA and nucleocapsid protein may control VSV genome replication. *Cell* 23: 837–845.
 56. Mottet-Osman G, Iseni F, Pelet T, Wiznerowicz M, Garcin D, et al. (2007) Suppression of the Sendai virus M protein through a novel short interfering RNA approach inhibits viral particle production but does not affect viral RNA synthesis. *J Virol* 81: 2861–2868.
 57. Reuter T, Weissbrich B, Schneider-Schaulies S, Schneider-Schaulies J (2006) RNA interference with measles virus N, P, and L mRNAs efficiently prevents and with matrix protein mRNA enhances viral transcription. *J Virol* 80: 5951–5957.
 58. Vidal S, Kolakofsky D (1989) Modified model for the switch from Sendai virus transcription to replication. *J Virol* 63: 1951–1958.
 59. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, et al. (2009) RIG-I-dependent sensing of poly (dA: dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. *Nat Immunol* 10: 1065–1072.
 60. Patel JR, Jain A, Chou Yy, Baum A, Ha T, et al. (2013) ATPase-driven oligomerization of RIG-I on RNA allows optimal activation of type-I interferon. *EMBO reports* 14: 780–787.
 61. Gorbalenya AE, Koonin EV, Donchenko AP, Blinov VM (1989) Two related superfamilies of putative helicases involved in replication, recombination, repair and expression of DNA and RNA genomes. *Nucleic Acids Res* 17: 4713–4730.
 62. Randall RE, Goodbourn S (2008) Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. *J Gen Virol* 89: 1–47.
 63. Gerlier D, Valentin H (2009) Measles virus interaction with host cells and impact on innate immunity. *Measles: Springer*. pp. 163–191.
 64. Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* 10: R25.
 65. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The sequence alignment/map format and SAMtools. *Bioinformatics* 25: 2078–2079.
 66. Plumet S, Gerlier D (2005) Optimized SYBR green real-time PCR assay to quantify the absolute copy number of measles virus RNAs using gene specific primers. *J Virol Methods* 128: 79–87.
 67. Sparrer KM, Pfaller CK, Conzelmann K-K (2012) Measles virus C protein interferes with Beta interferon transcription in the nucleus. *J Virol* 86: 796–805.



Identification of an LGP2-associated MDA5 agonist in picornavirus-infected cells

Safia Deddouche¹, Delphine Goubau¹, Jan Rehwinkel^{1†}, Probir Chakravarty², Sharmin Begum³, Pierre V Maillard¹, Annabel Borg⁴, Nik Matthews³, Qian Feng⁵, Frank J M van Kuppeveld⁵, Caetano Reis e Sousa^{1*}

¹Immunobiology Laboratory, Cancer Research UK, London Research Institute, London, United Kingdom; ²Bioinformatics Laboratory, Cancer Research UK, London Research Institute, London, United Kingdom; ³Clonal Sequencing Laboratory, Cancer Research UK, London Research Institute, London, United Kingdom; ⁴Protein Purification Laboratory, Cancer Research UK, London Research Institute, London, United Kingdom; ⁵Virology Division, Department of Infectious Diseases and Immunology, Utrecht University, Utrecht, Netherlands

*For correspondence: caetano@cancer.org.uk

Present address: [†]Medical Research Council Human Immunology Unit, Radcliffe Department of Medicine, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

Competing interests: The authors declare that no competing interests exist.

Funding: See page 17

Received: 13 September 2013

Accepted: 07 January 2014

Published: 18 February 2014

Reviewing editor: Zhijian J Chen, Howard Hughes Medical Institute, University of Texas Southwestern Medical School, United States

© Copyright Deddouche et al. This article is distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use and redistribution provided that the original author and source are credited.

Abstract The RIG-I-like receptors RIG-I, LGP2, and MDA5 initiate an antiviral response that includes production of type I interferons (IFNs). The nature of the RNAs that trigger MDA5 activation in infected cells remains unclear. Here, we purify and characterise LGP2/RNA complexes from cells infected with encephalomyocarditis virus (EMCV), a picornavirus detected by MDA5 and LGP2 but not RIG-I. We show that those complexes contain RNA that is highly enriched for MDA5-stimulatory activity and for a specific sequence corresponding to the L region of the EMCV antisense RNA. Synthesis of this sequence by in vitro transcription is sufficient to generate an MDA5 stimulatory RNA. Conversely, genomic deletion of the L region in EMCV generates viruses that are less potent at stimulating MDA5-dependent IFN production. Thus, the L region antisense RNA of EMCV is a key determinant of innate immunity to the virus and represents an RNA that activates MDA5 in virally-infected cells.

DOI: [10.7554/eLife.01535.001](https://doi.org/10.7554/eLife.01535.001)

Introduction

Viral infection in mammals triggers a rapid innate immune response involving the production of antiviral proteins and proinflammatory mediators, prominent among which are the type I interferons (IFN- α/β ; hereafter, IFN) (Stetson and Medzhitov, 2006; Takaoka and Yanai, 2006). IFNs are secreted cytokines that act on all nucleated cells to induce the transcription of more than 300 IFN-stimulated genes, whose products collectively limit virus replication and spread (Haller et al., 2007; Schoggins and Rice, 2011). IFN gene transcription is triggered by the activation of pattern recognition receptors that detect viral invasion. These receptors include members of the RIG-I-like receptor (RLR) family (Goubau et al., 2013), a sub-group of DExD/H-box helicases that surveys the cytosol for the presence of atypical RNAs associated with viral infection. The RLR family comprises three members: RIG-I (retinoic acid-induced gene 1), MDA5 (melanoma differentiation-associated gene 5), and LGP2 (laboratory of genetics and physiology 2). Binding of agonistic RNA by RIG-I or MDA5 triggers a signalling cascade that leads to the activation of transcription factors, including several of the IFN regulatory factors (IRFs), which translocate into the nucleus to induce expression of IFN and other genes. LGP2 lacks a signalling domain and cannot act in the same manner. Rather, LGP2 is thought to potentiate MDA5-dependent IFN induction although the exact mechanism by which this occurs remains unclear (Satoh et al., 2010; Bruns et al., 2012; Childs et al., 2013).

eLife digest A virus is basically molecules of DNA or RNA inside a protein shell, and in order to reproduce, it must infect a living cell and take control of it. However, the attacked cell will fight back and try to eliminate the invader. Activation of this so-called innate immune response requires the host cells to recognize that they have been infected, which they do by detecting the tell-tale molecules that indicate the presence of the virus.

When an RNA virus infects a cell, the tell-tale molecules are often atypical RNA molecules carried by the virus or produced as the virus replicates. Recognition of this 'foreign' material by receptor proteins inside the cell triggers the production of molecules called interferons, which activate the innate defence systems that eliminate the virus.

Different receptor proteins recognize different RNA viruses. For example, a receptor called MDA5 is known to respond to the picornaviruses, some of which can cause inflammation of the brain and heart muscle. However, the identities of the specific RNA molecules that are recognized by the MDA5 receptor have not been known. Deddouche et al. have now identified one such RNA molecule with the help of a second receptor protein, called LGP2.

The LGP2 receptor is not able to give the signal to produce interferons, so it is thought to work by binding to the RNA molecule to form a complex that is then relayed to MDA5 to give this signal. By isolating the complexes of LGP2 receptor from picornavirus-infected cells and sequencing the associated RNA, it was possible to identify the mystery RNA trigger. Deddouche et al. then tested picornaviruses in which this piece of RNA had been deleted from the genome, and found that the mutant viruses triggered a much weaker interferon response. By providing insight into the ways that some viruses are detected by the innate immune system, this research may inform future work on the development of new treatments to control viral infection.

DOI: [10.7554/eLife.01535.002](https://doi.org/10.7554/eLife.01535.002)

MDA5 and RIG-I are activated by different RNA viruses (Kato et al., 2006). RIG-I is non-redundant for detection of influenza or Sendai virus but dispensable for responses to picornaviruses whereas the opposite is the case for MDA5 (Kato et al., 2006; 2008). The basis for these differences stems from the ability of RIG-I and MDA5 to recognize different RNA patterns. RIG-I binds to and is activated by base-paired RNA containing a 5' triphosphate extremity (Hornung et al., 2006; Pichlmair et al., 2006; Schlee et al., 2009; Schmidt et al., 2009) as found in influenza and Sendai virus genomes (Baum et al., 2010; Rehwinkel et al., 2010; Weber et al., 2013). In contrast, MDA5 recognizes RNA independently of 5' phosphates and can be activated in cells by transfection of synthetic poly I:C or the double-stranded (ds) RNA genome segments of reovirus (Kato et al., 2006, 2008). Based on such observations, it has been concluded that MDA5 detects long dsRNA generated during virus infection. However, natural MDA5 agonists derived from infected cells remain poorly characterised. Some studies have suggested that they might correspond to high molecular weight RNA complexes containing double and single-stranded (ss) regions (Pichlmair et al., 2009). Other reports have proposed that relevant MDA5 agonists are specific viral replication intermediates (Feng et al., 2012; Triantafilou et al., 2012). Finally, it has been suggested that MDA5 might also be activated by RNA products of RNaseL cleavage (Malathi et al., 2010; Luthra et al., 2011) or by mRNA bearing unmethylated cap structures (Züst et al., 2011). Altogether, these studies provide a glimpse into the possible nature of MDA5 agonists in virally-infected cells but fall short of identifying them with precision.

Immunoprecipitation of RIG-I from cells infected with influenza A virus (IAV) or Sendai virus has allowed the identification of physiological RIG-I agonists (Baum et al., 2010; Rehwinkel et al., 2010). In this study, we use an analogous approach to investigate the nature of MDA5 agonists in cells infected with encephalomyocarditis virus (EMCV), a member of the *Cardiovirus* genus of picornaviruses. Picornaviruses are single-stranded positive-strand (sense) RNA viruses that replicate in infected cells via a negative-strand (antisense) intermediate. We purify RNA directly from complexes obtained by immunoprecipitation of LGP2 and show that this method enriches for MDA5 stimulatory RNA corresponding to a portion of the EMCV antisense RNA. Deletion of the region encoding this antisense RNA generates viruses that produce less stimulatory RNA and are less potent at inducing IFN in infected cells or mice. Conversely, in vitro synthesis of the same sequence generates an MDA5 agonistic RNA. Thus, a discrete region of the EMCV negative-strand RNA acts as a physiologically-relevant MDA5 agonist in infected cells.

Results

EMCV replication is required for MDA5/LGP2-dependent IFN induction

To confirm that both MDA5 and LGP2 are required for IFN responses to EMCV (Kato et al., 2006; Satoh et al., 2010), we used mouse embryonic fibroblasts (MEFs) carrying null mutant alleles of the genes *Ifih1* and *Dhx58* encoding MDA5 and LGP2, respectively. We infected *Ifih1*^{-/-} (MDA5-deficient), *Ifih1*^{+/-} (MDA5-sufficient), *Dhx58*^{-/-} (LGP2-deficient) or *Dhx58*^{+/-} (LGP2-sufficient) MEFs and assessed the induction of IFN- β and the interferon-stimulated protein IFIT-1. The upregulation of *Ifit1* or *Ifnb1* mRNA was greatly impaired in MDA5- or LGP2-deficient MEFs infected with EMCV (Figure 1—figure supplement 1A,B). The same cells responded normally to RIG-I-dependent viruses such as IAV and to known RIG-I agonists such as in vitro transcribed (IVT) RNA (Figure 1—figure supplement 1A,B). To begin to define the MDA5/LGP2 agonist, we isolated the EMCV genome from purified EMCV particles and transfected it into reporter cells together with a plasmid encoding a luciferase gene under the control of the IFN- β promoter. As reporter cells, we used an easily transfectable subclone of HEK293 cells that expresses all RLRs (Figure 1—figure supplement 2A) and can respond, albeit weakly, to MDA5 agonists (data not shown; Figure 1). Because transfection of positive-stranded viral RNA can lead to viral replication (even though EMCV replicates in HEK293 cells only poorly), we performed the IFN reporter assay in the presence of ribavirin, an inhibitor of viral RNA synthesis. As seen in Figure 1A, EMCV genomes did not stimulate the IFN- β reporter, in contrast to the genomes of IAV, which directly activate RIG-I (Baum et al., 2010; Rehwinkel et al., 2010; Weber et al., 2013). To determine whether viral replication generates stimulatory RNA, we extracted total RNA from HeLa cells that had been infected with EMCV in the presence or absence of ribavirin. RNA isolated from cells in which EMCV viral replication had been permitted to take its course (DMSO control) potently induced the IFN- β reporter upon transfection into HEK293 cells (Figure 1B). In contrast, RNA extracted from HeLa cells treated with ribavirin was non-stimulatory (Figure 1B). Treatment of the reporter HEK293 cells themselves with ribavirin did not affect the response (Figure 1—figure supplement 2B,C), which indicates that the stimulatory RNA is preformed in EMCV-infected HeLa cells. Furthermore, the response in the HEK293 reporter cells was dependent on MDA5 as demonstrated using RNA interference-mediated MDA5 knockdown (Figure 1—figure supplement 2D). Altogether these data indicate that MDA5 and LGP2 activation results exclusively from RNA generated during active EMCV replication, as recently suggested (Feng et al., 2012; Triantafilou et al., 2012).

One feature of the replication cycle of positive-strand RNA viruses is the generation of a negative-strand RNA that, together with the annealed positive strand, forms a long dsRNA structure. To characterise the ‘strandedness’ of the IFN stimulatory RNA generated upon EMCV replication, we extracted total RNA from non-infected or either IAV or EMCV-infected HeLa cells and separated it into ds and ssRNA fractions (Feng et al., 2012). As expected (Pichlmair et al., 2006), the ssRNA but not the long dsRNA fraction extracted from cells infected with IAV, stimulated the IFN reporter (Figure 1C,D). In contrast, both ds and ssRNA fractions from cells infected with EMCV triggered the IFN- β reporter (Figure 1C,D). Similarly, treatment of total RNA from EMCV-infected cells with RNase A or RNase III, which digest unpaired or base-paired RNA, respectively, strongly reduced stimulatory activity (Figure 1E). In contrast, removal of 5' phosphates by digestion with calf intestinal phosphatase (CIP) or 5' polyphosphatase (PP) did not impact stimulatory activity although it abrogated that of IVT control RNA (Figure 1E). Altogether these data indicate that MDA5/LGP2 stimulatory RNA accumulates in EMCV-infected cells during virus replication and contains both ssRNA and dsRNA features, as previously suggested (Pichlmair et al., 2009).

Enrichment of MDA5 agonists from EMCV-infected cells by LGP2 pulldown

To further purify the RNA responsible for activation, we established a method to isolate LGP2-associated RNA from infected cells. We immunoprecipitated (IP) LGP2 from EMCV-infected HeLa cells transiently expressing a FLAG-tagged LGP2 protein (Figure 2A), extracted RNA from the precipitates and analysed its stimulatory activity in reporter cells (Figure 2B). Notably, RNA associated with the LGP2 precipitates, but not with control (ctrl) precipitates, stimulated the IFN- β luciferase reporter in HEK293 cells and induced expression of the *IFNB1* gene in HeLa cells (Figure 2B,C). Moreover, when compared to input material, stimulatory activity was significantly enriched in the LGP2-immunoprecipitate and was selectively depleted from the unbound fraction (Figure 2B,C). We additionally transfected the LGP2-associated RNA into MEFs and confirmed its ability to stimulate IFN production by ELISA (Figure 2D).




Figure 1. IFN- α/β induction requires EMCV replication. (A) EMCV and IAV RNA genomes were extracted from purified viral particles and tested at the indicated doses in an IFN- β promoter luciferase reporter assay in HEK293 cells in the presence of ribavirin. IVT-RNA was included as a positive control. (B) HeLa cells were infected with EMCV (MOI 1) for 16 hr in the presence of DMSO or ribavirin. RNA was extracted (HeLa EMCV RNA) and tested at the indicated doses in the IFN- β promoter luciferase reporter assay in HEK293 cells. RNA extracted from uninfected HeLa cells (NI RNA) and IVT-RNA were included as negative and positive controls, respectively. (C and D) HeLa cells were either not infected (NI) or infected with EMCV or IAV at MOI 1 for 16 hr. RNA was extracted from cell lysates and separated into double-stranded (ds; panel C) or single-stranded (ss; panel D) fractions. The fractions were analysed on a 1% agarose gel and the indicated amounts of RNA were then tested at the indicated doses in the IFN- β promoter luciferase reporter assay in HEK293 cells. dsRNA bands are indicated on the gel picture. ssRNA runs as a smear and only the ribosomal RNA bands are identifiable, as indicated. ssRNA was used as a ladder. Although the experiment depicted was carried out in the absence of ribavirin, identical results were obtained in the presence of the drug indicating that the stimulatory capacity of ssRNA fractions is not due to subsequent replication and formation of dsRNA (data not shown). (E) Total RNA from HeLa cells infected with EMCV at MOI 1 for 16 hr (HeLa EMCV RNA) or control IVT RNA was either left untreated (NT) or digested with calf intestinal phosphatase (CIP), base-paired specific RNase (RNaseIII), 5' RNA polyphosphatase (PP), or single-strand-specific RNase (RNaseA). Digested RNA samples were analysed on a 1% agarose gel and the indicated amounts of RNA were tested in the IFN- β promoter luciferase reporter assay in HEK293 cells. One representative of three (A, C, D) or two (B and E) experiments is shown.

DOI: [10.7554/eLife.01535.003](https://doi.org/10.7554/eLife.01535.003)

The following figure supplements are available for figure 1:

Figure supplement 1. LGP2 and MDA5 are required for IFN- α/β production in response to EMCV.

DOI: [10.7554/eLife.01535.004](https://doi.org/10.7554/eLife.01535.004)

Figure supplement 2. Ribavirin abrogates EMCV RNA infectivity but does not decrease IFN- β reporter activity in 293 cells.

DOI: [10.7554/eLife.01535.005](https://doi.org/10.7554/eLife.01535.005)




Figure 2. LGP2 pulldown captures MDA5 agonistic RNA from EMCV-infected cells. **(A)** Schematic representation of the experimental setup for LGP2 immunoprecipitation (IP). Precipitation efficiency was routinely verified by immunoblotting with an anti-FLAG antibody; an example is shown in the lower panel. **(B and C)** The indicated amounts of RNA from EMCV-infected FLAG-LGP2-expressing HeLa cells (input), RNA associated with LGP2 or control Figure 2. Continued on next page

Figure 2. Continued

(ctrl) immunoprecipitations (IP), or RNA remaining after LGP2 or control precipitations (unbound) were tested for the ability to stimulate the IFN- β promoter reporter assay in HEK293 cells (B) or induce IFNB1 mRNA (normalised to GAPDH) in HeLa cells (C). (D) The indicated amounts of RNA from samples processed as in (B) and (C) were transfected into WT, LGP2-deficient, or MDA5-deficient MEFs. Supernatants were harvested 16 hr later and mIFN- α levels measured by ELISA (left panel). I.V.T RNA transfections were used as positive controls (right panel). Error bars represent the standard deviation of three replicate transfections. (E) LGP2-associated RNA was not treated (NT) or digested with RNaseT1 (specific for ssRNA), RNaseIII (specific for base-paired RNA), CIP or Terminator (Term, an RNase specific for 5' monophosphate RNA) and subsequently tested for the ability to stimulate the IFN- β reporter in HEK293 cells. The activity of all enzymes was validated in control samples (not shown). (F) RNA from HeLa cells infected with EMCV (input) was incubated with recombinant FLAG-tagged LGP2 protein and anti-FLAG or control IP was performed as in (A). IP-associated RNA was isolated and tested, in parallel with input RNA, at the indicated doses in the IFN- β promoter luciferase reporter assay on HEK293 cells. Schematic representation of the experiment is shown on the left, results are presented on the right. One representative of the three (A–C) or two (D–F) experiments is shown.

DOI: 10.7554/eLife.01535.006

Importantly, activity was lost in LGP2- or MDA5-deficient MEFs (Figure 2D), indicating that the LGP2-associated RNA isolated from immunoprecipitates is a pure MDA5/LGP2 agonist. Consistent with this notion, its IFN stimulatory capacity was unaffected by treatment with CIP, which inactivates most RIG-I agonists, or Terminator (Term), which digests RNA with 5' monophosphates (Figure 2E). Furthermore, digestion with RNaseT1 and RNaseIII completely abolished stimulatory potential (Figure 2E), again suggesting the presence of unpaired and base-paired RNA regions as previously observed with total RNA from EMCV-infected cells (Figure 1E). Finally, we incubated purified RNA from EMCV-infected HeLa cells together with recombinant FLAG-tagged LGP2 (Figure 2F). FLAG immunoprecipitation allowed enrichment for stimulatory activity when compared to a control IP, demonstrating that stimulatory RNA can associate with LGP2 in vitro in the absence of additional proteins (Figure 2F). Altogether these results indicate that LGP2 selectively associates with a pool of MDA5 agonists in EMCV-infected cells and that LGP2 IP is a suitable approach to enrich for such agonists.

L region antisense EMCV RNA is selectively enriched in LGP2 precipitates

Having established a method to purify IFN stimulatory RNA from LGP2/RNA complexes isolated from EMCV-infected HeLa cells, we subjected it to deep sequencing analysis. We pooled RNA extracted from multiple independent control or LGP2 IPs and carried out Illumina sequencing in duplicate ('Material and methods'). Approximately, 30 million reads of 60 nts in length were obtained from each sequencing sample and were mapped to the human and the EMCV genomes. The total number of reads mapping to EMCV represented around 30% in LGP2 IP samples vs only 4% and 6% in ctrl IP and input, respectively (Tables 1 and 2; Figure 3A), which indicated that the RNA in the LGP2 IP is specifically enriched for EMCV-derived sequences. To allow better comparison across samples, the number of reads from LGP2 IP, ctrl IP and input samples was first normalised to the total number of reads (displayed as reads/million) and then aligned to the EMCV genome (Figure 3, Figure 3—figure supplement 1). Surprisingly, the distribution of sequences in the LGP2 IP sample was not uniform but displayed a number of discrete peaks concentrated in the 5' region of the EMCV genome. In particular, one peak from position 735 nts to 905 nts on the antisense RNA was strongly enriched (25,000 reads/million) over input and ctrl IP samples (non detectable and 60 reads/million, respectively) (Figure 3B). A smaller peak ($\pm 5,000$ reads/million) in the corresponding part of the sense strand was also enriched in LGP2 IP samples (Figure 3B). This region encodes the leader (L) protein of EMCV and is henceforth referred to as the L region.

Table 1. Total number of reads aligning to the EMCV genome in LGP2 IP, ctrl IP, or input samples

	LGP2 IP	ctrl IP	input
Number of reads*	31,662,255	37,235,332	35,725,972
EMCV	2,747,427	243,472	1,380,128
EMCV (+)	1,305,129	239,625	1,380,058
EMCV (–)	1,442,298	3,847	70

*Total numbers of reads, reads matching both strands (EMCV), sense strand (EMCV (+)) or antisense strand (EMCV (–)) of EMCV RNA sequences.

DOI: 10.7554/eLife.01535.007

Table 2. Percentage of reads mapping either the sense (+) or the antisense (–) strand in the L region compared to the full length EMCV genome

	L region		Total EMCV	
	(+)	(–)	(+)	(–)
LGP2 IP	19.49	80.51	47.50	52.50
ctrl IP	78.55	21.45	98.17	1.83
input	100.00	0.00	100.00	0.00

DOI: [10.7554/eLife.01535.008](https://doi.org/10.7554/eLife.01535.008)

To validate these findings, we used strand-specific RT-PCR with primers for the L antisense or, as a control, the VP1 antisense regions (primer localisation indicated by red arrows on the schematic representation of the EMCV genome in **Figure 3B**). This analysis confirmed that the L antisense but not the VP1 antisense region, was enriched in LGP2 IP samples compared to ctrl IPs and input material (**Figure 3C**). These findings were further validated in the LGP2 in vitro reconstitution assay, which confirmed that RNA that binds to LGP2 is enriched for the L antisense region (**Figure 3—figure supplement 2**). In sum, LGP2 association with EMCV RNA is strongly biased towards a discrete area of the negative (antisense) strand of the L protein-encoding region.

We next examined if the L antisense (AS) RNA sequence was sufficient to trigger an MDA5-dependent IFN response. We generated, by in vitro transcription, RNAs corresponding either to the AS or the sense strand of the EMCV L region. After CIP treatment to remove any RIG-I-stimulatory activity linked to the presence of the 5' triphosphates, we tested the stimulatory potential of these RNAs in MEFs deficient for the *Ddx58* gene encoding RIG-I or in MDA5-deficient MEFs by IFN- β promoter luciferase assay (**Figure 4A,B**). The RNA containing the L AS derived sequence was clearly stimulatory in contrast to the one derived from the L sense sequence. Moreover, the activity of the CIP-treated L AS was greatly reduced in the MDA5-deficient but not RIG-I-deficient MEFs (**Figure 4A**). As a control, we used non-CIP treated IVT RNA corresponding to the sense sequence of the neomycin gene (**Rehwinkel et al., 2010**), which showed the expected RIG-I dependence (IVT RNA, **Figure 4C**). We conclude that an IVT RNA corresponding to the EMCV L AS RNA sequence found in LGP2 immunoprecipitates (**Figure 3**) can trigger an MDA5-dependent IFN response.

The L region of EMCV is required for generation of LGP2-associated stimulatory RNA

To ask whether the L region of the EMCV genome is important for the generation of IFN stimulatory RNA, we used mutant EMCV viruses with partial (EMCV $\Delta_{L_{ac}}$ and EMCV $\Delta_{L_{zn}}$) or complete (EMCV Δ L) deletions of that region (**Dvorak et al., 2001; Figure 5A**). We infected HeLa cells, extracted RNA and subjected it to RT-PCR analysis. Using specific primers (shown as arrows in **Figure 5A**), we confirmed the loss of the L region in the mutant viruses (**Figure 5B**, left panel). Because all three viruses are attenuated due to the absence of the L protein, a known antagonist of IFN induction (**Hato et al., 2007**), we also amplified the Vp1 region to verify that similar levels of EMCV RNA were present in all samples (**Figure 5B**, right panel). We then assessed the IFN stimulatory potential of these samples using the IFN- β reporter assay. In all cases, RNA extracted from HeLa cells infected with EMCV $\Delta_{L_{ac}}$, $\Delta_{L_{zn}}$ or Δ L was slightly less stimulatory than RNA extracted from cells infected with wild-type (WT) EMCV (**Figure 5C**). More importantly, only a low amount of stimulatory RNA was recovered from LGP2 IPs following infection with the mutant viruses in contrast to infection with WT EMCV (**Figure 5D**). These results are consistent with the earlier indications that the major species of stimulatory RNA associating with LGP2 in EMCV-infected cells derives from the L antisense region.

Deletion of the L region results in a virus that is both depleted of L RNA and L protein. To verify that the lack of LGP2-associated stimulatory RNA upon infection with $\Delta_{L_{ac}}$, $\Delta_{L_{zn}}$ or Δ L viruses was due to the absence of L region RNA rather than absence of L protein function, we additionally used an EMCV Zn_{C19AC22A} strain. This virus carries two mutations in the zinc domain of the L protein, which inactivate function (**Hato et al., 2007**) but should not impact on the production of L RNA (even if that RNA now carries two nucleotide substitutions). Reassuringly, the amount of stimulatory RNA in total cell extracts (**Figure 5E**) or associated with LGP2 precipitates (**Figure 5F**) was comparable upon infection with EMCV Zn_{C19AC22A} and EMCV WT even though, as before, it was markedly reduced after EMCV Δ L infection




Figure 3. The L antisense RNA region is enriched in LGP2 pulldowns from EMCV-infected cells. **(A)** RNA from LGP2 IP, control (ctrl) IP, or total RNA (input) from EMCV-infected cells (**Figure 2A,B**) was sequenced. Reads corresponding to human or EMCV sequences are shown as a percentage of the total number of reads that could be aligned to any sequence in bioinformatic databases. **(B)** All reads obtained from LGP2 IP or ctrl IP from EMCV infected cells were normalised to the number of reads per million to allow for comparison across samples. Results were mapped to the EMCV genome (depicted above; the red arrows indicate the respective position of the primer used for the reverse transcription prior to quantitative RT-PCR in **[C]**). The total numbers of reads are shown in **Table 1**. The vertical axis shows the number of normalised reads mapping to a particular position on the EMCV genome (horizontal axis). The positive and negative numbers represent reads that align to the sense or the antisense strand, respectively. Numbering along the x-axis indicates nucleotide position on the sense (+) strand. One experiment of two is shown. **(C)** The amount of L antisense (AS) (primer 1 in **B**) or VP1 AS (primer 2 in **B**) RNA was analysed by strand-specific RT-PCR in LGP2 IP, ctrl IP, and input samples from an independent experiment. Vertical Figure 3. Continued on next page

Figure 3. Continued

axis represents RNA level, calculated relative to the data obtained from a standard curve of cDNA from EMCV-infected cells. Error bars represent the standard deviation of four independent samples. ns = not significant.

DOI: [10.7554/eLife.01535.009](https://doi.org/10.7554/eLife.01535.009)

The following figure supplements are available for figure 3:

Figure supplement 1. Comparison of read-distribution along the EMCV genome for LGP2-associated RNA and input material.

DOI: [10.7554/eLife.01535.010](https://doi.org/10.7554/eLife.01535.010)

Figure supplement 2. LGP2 directly binds L region antisense RNA.

DOI: [10.7554/eLife.01535.011](https://doi.org/10.7554/eLife.01535.011)

(**Figure 5E,F**). We conclude that the lack of stimulatory LGP2-associated RNA observed after infection with EMCV Δ L is specifically due to the loss of L region RNA rather than the loss of L protein function.

L region RNA is required for innate detection of EMCV

We subsequently assessed the importance of the L RNA sequence for IFN responses in primary cells by comparing infection with EMCV Δ L and EMCV Zn_{C19AC22A} mutant viruses. We used dendritic cells grown from mouse bone marrow (BM-DCs), which produce vast amounts of IFNs in response to virus infection (**Diebold et al., 2003**). To allow efficient replication of the L protein-deficient viral strains, BM-DCs were derived from IFN- α/β receptor-deficient mice (IFNAR1 knockout [KO]). To monitor EMCV detection and the activation of the downstream RLRs signalling pathway, we assessed the induction of both *Irf1* and *Irf3*, which are direct transcriptional targets of IRF-3 (**Grandvaux et al., 2002**). Upon infection with WT EMCV, induction of *Irf1* and *Irf3* was limited (**Figure 6A,B**). It was markedly greater in response to infection with EMCV Zn_{C19AC22A}, which encodes the non-functional mutant L protein (**Figure 6A,B**), consistent with the fact that the L protein inhibits IFN induction (**Hato et al., 2007**). In contrast, infection with EMCV Δ L lacking both L protein and EMCV L region RNA induced lower levels of *Irf3* or *Irf1* than infection with EMCV Zn_{C19AC22A} at two different multiplicities of infection (MOI) (**Figure 6A,B**). EMCV Δ L and EMCV Zn_{C19AC22A} replicated to similar levels, indicating that any differences in stimulation by these viruses are not caused by variations in viral RNA levels (**Figure 6C**). Similar results were obtained when the mutations were introduced into the EMCV mengo strain background (data not shown). These data show that the L region RNA of EMCV is important for RLR stimulation and viral restriction in infected cells and that this is independent on its ability to encode a functional L protein.

In parallel, we also examined the IFN response to infection with an EMCV mengo strain mutant virus carrying the L region of the foot-and-mouth disease virus (FMDV). FMDV belongs to a different picornavirus genus and the FMDV L region sequence and FMDV leader protein share little similarity with those of EMCV. Notably, the induction of both *Irf1* and *Irf3* in response to EMCV_{FMDV} was comparable to that induced by EMCV Δ L (**Figure 6A,B**) and replication of the two strains was indistinguishable.




Figure 4. In vitro transcribed L AS RNA triggers an MDA5-dependent IFN response. (**A–C**) L antisense (AS) (**A**), L sense (**B**) or IVT RNA (**C**) sequences were in vitro transcribed and all RNA except from the control IVT RNA (**C**) were CIP treated to remove any 5' phosphates. The indicated amount of RNA were then transfected into RIG-I-, MDA5-deficient or sufficient MEFs expressing the IFN- β reporter. Reporter activity was measured 16 hr later. One of two experiments is shown.

DOI: [10.7554/eLife.01535.012](https://doi.org/10.7554/eLife.01535.012)




Figure 5. The L region of EMCV is required for the generation of LGP2-associated stimulatory RNA. **(A)** Schematic representation of the L region of EMCV genome and L region mutant viruses used in this study. The crosses indicate the position of the two point mutations in EMCV Zn_{C19AC22A}. The marked positions indicate the limits of the deletions present in EMCV ΔL, ΔLac, and ΔLzn, respectively. **(B–F)** FLAG-LGP2-expressing HeLa cells were infected with EMCV WT, Zn_{C19AC22A}, ΔL, ΔLac, or ΔLzn viruses at MOI 1 for 16 hr before lysis and total RNA extraction (input; **B, C, E**) or lysis followed by LGP2 or control (ctrl) immunoprecipitation and RNA extraction from precipitates (IP; **D and F**). **(B)** Quantitative RT-PCR analysis of viral sequences in input samples using primers specific for the L region (left panel) or the Vp1 region (right panel) and normalised to GAPDH. ND = non-detected. The position of the primers used for amplifying the L region is depicted in **(A)**. **(C–F)** The stimulatory potential of the indicated doses of input (**C and E**), LGP2 IP or ctrl IP RNA (**D and F**) was assessed by IFN-β promoter luciferase reporter assay in HEK293 cells. **(B–F)** One experiment of two is shown.

DOI: [10.7554/eLife.01535.013](https://doi.org/10.7554/eLife.01535.013)

The following figure supplements are available for figure 5:

Figure supplement 1. 200 ng of RNA isolated from HeLa cells infected with EMCV WT, Zn_{C19AC22A} or ΔL at MOI 1 for 16 hr (HeLa EMCV RNA) was transfected into MDA5-sufficient or MDA5-deficient bone marrow-derived DCs in presence of ribavirin.

DOI: [10.7554/eLife.01535.014](https://doi.org/10.7554/eLife.01535.014)

These data suggest that the EMCV L AS RNA sequence rather than the position of the L region in the EMCV genome is the key determinant in innate stimulation. To further address this issue, we introduced the EMCV L antisense RNA sequence into the influenza virus NS segment, a known RIG-I agonist




Figure 6. L region RNA is required for IFN- α/β production in response to EMCV. (A–C) IFNAR1-deficient GM-CSF bone marrow-derived DCs were either not infected (NI) or infected with the indicated viruses at an MOI of 1 or 10. Levels of *Ifit1* (A), *Ifnb1* (B) or EMCV Vp1 (C) RNA were analysed 16 hr later by quantitative RT-PCR and normalised to *gapdh*. (D and E) 293T cells were transfected with the influenza vRNP reconstitution system using the influenza NS wt segment or NS segment carrying the L AS RNA sequence and incubated for 24 hr. RNA was then extracted and the IFN stimulatory activity was tested on MEF wt, MDA5 or RIG-I deficient by luciferase assay (D) and the expression of the L AS sequence was verified by strand-specific RT-qPCR with primer specific for the L antisense RNA (E). (A–E) One experiment of two is shown.

DOI: 10.7554/eLife.01535.015

(Rehwinkel et al., 2010). However, as shown in **Figure 6D,E**, the resulting chimeric NS RNA remained dependent on RIG-I and not MDA5 for its stimulatory activity. This suggests that the L region antisense sequence needs to be somehow processed or released in the context of EMCV infection to trigger an MDA5-dependent response and this does not happen in the context of the influenza virus NS segment.

Finally, we assessed whether L region RNA is also important for responses to EMCV in vivo. Mice deficient in IFNAR1 (to allow replication of the attenuated viruses) were infected with EMCV WT, EMCV Δ L and EMCV Zn_{C19AC22A} strains and the outputs of innate immune stimulation were measured. Higher levels of IFN- α were found in the serum of mice 24 hr after infection with EMCV Zn_{C19AC22A} when compared to EMCV Δ L and WT (**Figure 7A**). In addition, the expression of *Ifit1* and *Ifnb1* was also much higher in hearts from mice infected with EMCV Zn_{C19AC22A} compared to mice infected with EMCV Δ L and WT (**Figure 7B,C**). Measurement of VP1 mRNA in hearts confirmed broadly similar levels of infection by all viruses (**Figure 7D**). We conclude that the presence of L region RNA independently of the function of the L protein is important for innate immune responses to EMCV infection in vivo.

Discussion

Several types of RNA can trigger MDA5-dependent responses in experimental settings (Malathi et al., 2007, 2010; Pichlmair et al., 2009; Luthra et al., 2011; Züst et al., 2011; Feng et al., 2012; Triantafilou et al., 2012) but it remains unclear which RNAs serve as natural MDA5 agonists during virus infection. For example, some of the RNA species extracted from infected cells may not have access to MDA5 during infection or may be produced in quantities or at times that are irrelevant for innate immune recognition. One way to identify those RNAs most likely to be relevant agonists in infected cells is to isolate them directly from RLR complexes present in those cells (Baum and García-Sastre, 2010; Rehwinkel et al., 2010). In this study, we describe a method to isolate relevant MDA5 agonists from cells infected with EMCV by immunoprecipitation of LGP2/RNA complexes. We show that this




Figure 7. The L region is required for IFN- α/β responses to EMCV in vivo. (**A** and **B**) IFNAR1 KO mice were injected intraperitoneally with PBS (not infected; NI) or with 10^6 pfu of the indicated viruses. (**A**) mIFN- α levels in the serum were measured by ELISA after 24 hr. (**B–D**) RNA was extracted from hearts 24 hr postinfection and analysed by quantitative RT-PCR for levels of *Ifit1* (**B**), *Ifnb1* (**C**), or EMCV Vp1 (**D**) RNA normalised to *gapdh* expression. Combined results of two independent experiments are shown. Each symbol represents an individual mouse. ns = not significant. DOI: 10.7554/eLife.01535.016

method simultaneously enriches for MDA5 stimulatory activity and for a discrete species of antisense RNA mapping to the EMCV L region. Notably, we establish a causal connection between the two events by showing that deletion of the L region from the virus genome abrogates the association of stimulatory RNA with LGP2 in infected cells and reduces the innate stimulatory capacity of the virus, both in vitro and in vivo. Finally, we show that in vitro synthesis of L region antisense RNA is sufficient to generate an MDA5 agonist. Our results demonstrate that the antisense L region of EMCV associates with LGP2 and is a key determinant of MDA5 stimulation. Curiously, this determinant is derived from the same region that encodes a protein product that suppresses IFN induction. The fact that deletion of this region in EMCV reduces viral stimulatory activity is therefore counterintuitive and strengthens the notion that it is a physiologically-relevant major determinant of innate immunity to the virus.

The finding that pulldown of LGP2 allows isolation of MDA5 stimulatory RNA is in agreement with the fact that both RLRs are required for IFN production upon EMCV infection (**Figure 1—figure supplement 1**) and with previous reports describing LGP2 as a positive regulator of MDA5 signalling (Venkataraman et al., 2007; Satoh et al., 2010; Bruns et al., 2012; Childs et al., 2013). Interestingly, despite numerous attempts and experimental permutations, we have never been able to isolate stimulatory RNA directly from MDA5 pulldowns (data not shown). One explanation may be that LGP2 possesses higher avidity for RNA than MDA5 (Bruns et al., 2012; Childs et al., 2013) and is therefore more prone to retain bound agonist during cell lysis and precipitation. Another possibility relates to the fact that MDA5 forms filaments along RNA upon activation (Peisley et al., 2011, 2012; Berke and Modis, 2012; Berke et al., 2012; Wu et al., 2012) and that such structures—when formed in infected cells—may be difficult to isolate. These considerations raise the question of whether LGP2 precipitation selects relevant MDA5 agonists. For example, given that LGP2 can bind to stimulatory RNAs in vitro (**Figure 2F**), is it possible that the complexes that we precipitate result from post-lysis ‘mopping-up’ of stimulatory RNA that would never in the intact cell have come into contact with MDA5? We believe this is unlikely based on the fact that the functional relevance of the L region identified in the LGP2 pulldowns could be validated in the context of infection using mutant viruses. Furthermore, we find that LGP2 pulldown both enriches for MDA5 agonists and depletes them from input material. Therefore, it appears that the universe of LGP2-bound RNAs largely overlaps with that of MDA5 agonists in EMCV-infected cells. Although we do not exclude the possibility that there are MDA5 agonists that

are not captured by LGP2 pulldown (see below), our findings suggest a model where LGP2 pre-selects RNAs for MDA5 activation prior to the formation of MDA5 filaments. Whether the two proteins form a physical complex remains to be established—it is possible that LGP2 acts upstream of MDA5 to ‘handover’ agonistic RNA and that interaction with MDA5, if any, may be indirect or transient.

Deep sequencing of LGP2-associated stimulatory RNA was revealing. We were not able to identify specific enrichment for any human sequences (data not shown), a finding that does not support a dominant role for RNaseL cleaved self RNA in MDA5 activation (*Malathi et al., 2007*). This is in agreement with another recent publication that also failed to detect a significant role for RNaseL activity in EMCV-dependent IFN induction (*Feng et al., 2012*). Instead, the sequencing data, confirmed by strand-specific RT-PCR analysis, identified a different species of small RNA that was highly enriched in LGP2 pulldowns. This is a fragment of 171 nucleotides that corresponds to the antisense RNA in the L region of the genome. Its short length and failure to be accompanied by the complementary strand are at odds with the notion that MDA5 is activated by long dsRNA (*Kato et al., 2006, 2008*). However, recent data indicate that MDA5 can form filaments along short dsRNA of around 100 nucleotides in length (*Peisley et al., 2011*). Moreover, the fact that LGP2-associated RNA appears to be single-stranded is in agreement with the observation that the stimulatory activity of the LGP2-associated RNA is sensitive to RNases that degrade ssRNA (*Figure 2E*). Interestingly, this LGP2-associated RNA is also sensitive to dsRNase treatment, which suggests the presence of base-paired regions important for MDA5/LGP2 recognition. Consistent with that notion, heat denaturation destroyed its activity (data not shown). In silico analysis reveals the potential of the L antisense RNA to form hairpins (data not shown), and such secondary and tertiary structure features may help to efficiently trigger MDA5 activation. Interestingly, by in vitro transcription of a sequence corresponding to the L antisense region we have succeeded in creating de novo an RNA that triggers MDA5 activation (*Figure 4*). What endows this RNA with MDA5 agonistic activity and whether the in vitro transcribed version fully corresponds to that naturally formed in EMCV-infected cells will require further investigation.

Another intriguing question is how a fragment of L AS RNA is generated upon viral infection. We have not been able to find a report describing the generation of small antisense RNA fragments during EMCV replication. However, Northern blots of RNA from EMCV-infected cells screened with an L AS sequence probe reveal many fragments smaller than the EMCV genome ranging between 200 and 2000 nucleotides (data not shown). Moreover, a previous study has reported the generation of a short subgenomic RNA fragment derived from the degradation of the non-polyadenylated genome of flaviviruses by the exonuclease XRN1 (*Funk et al., 2010*). It is possible that a similar mechanism could generate an L antisense RNA fragment. Alternatively, stress granule formation, known to interfere with picornavirus replication (*Borghese and Michiels, 2011*), could potentially lead to degradation of viral RNA and generate the L region antisense RNA agonist. Interestingly, MDA5 and LGP2 have been recently shown to associate with stress granules (*Onomoto et al., 2012; Langereis et al., 2013*).

Picornavirus replication involves a stage where the positive-stranded genome anneals with a newly-formed negative strand in a full-length double-stranded RNA structure known as the replicative form (RF). Negative-strand RNA from the RF then serves as the template to produce new progeny viral genomes through a replicative intermediate (RI) consisting of many positively-stranded progeny RNA genomes in the process of being synthesised and still partially hybridised to the full-length antisense RNA template. A recent study showed that negative-strand RNA synthesis is absolutely required for IFN induction during infection of mengovirus, a strain of EMCV (*Feng et al., 2012*). Our results that a small RNA derived from the negative-strand RNA of EMCV associates with LGP2 and activates MDA5 is in line with that report. However, it has also been shown that both the RF and RI forms can activate MDA5 upon transfection (*Feng et al., 2012; Triantafilou et al., 2012*). It is conceivable that RF and RI forms could be processed by RNases within the cell following transfection or infection, releasing the L antisense fragment that associates with LGP2. Alternatively, it is possible that the L region antisense fragment enriched in our IP is only one of several agonists generated upon EMCV replication and that the RF and RI forms constitute a different set of agonists that do not strongly associate with LGP2 and have therefore been missed in our approach. This hypothesis is consistent with our data, which show that EMCV Δ L viruses still possess the ability to induce low levels of IFN and IFIT-1 (*Figures 6 and 7*) and generate stimulatory RNA (*Figure 5*). Such data suggest the existence of at least one additional stimulatory RNA species beside the L region antisense fragment and help explain why EMCV Δ L is an attenuated strain: the additional stimulatory RNA means that it cannot fully evade innate immune detection while the lack of the L protein means that it cannot suppress the consequences of detection. Although it remains to be established

whether this putative additional stimulatory RNA species corresponds to the RF/RI (or even acts via MDA5—**Figure 5—figure supplement 1**), these observations suggest the need to determine to what extent different innate immune stimuli dominate at different stages of infection.

Our investigation has resulted in the identification of a specific region of the EMCV negative-strand RNA as a determinant of innate immunity to the virus. To our knowledge, this is the first study to identify an MDA5 agonist bound to LGP2 in infected cells. Picornaviruses constitute a large family of viruses that encompasses many human and animal pathogens including some of economical or medical importance including Poliovirus, Coxsackievirus, Rhinovirus, and EMCV (**Tuthill et al., 2010**). The L regions of picornaviruses can show wide variation and it will be interesting to determine to what extent L region RNA or other small RNAs can act as MDA5 agonists across picornavirus genera. Elucidating the molecular basis of picornavirus detection will help understand the general rules underlying innate virus detection and may suggest new strategies to control viral infection.

Material and methods

Reagents

The human LGP2 sequences were amplified from cDNA derived from IFN- α /D (PBL Assay Science, Piscataway, NJ)-treated HEK293 cells using a forward primer containing the 3xFLAG epitope sequence with the following oligos (FW LGP2: 5'gccgccatggactacaagaccatgacgggtgattataaagatcatgacatcgattacaag-gatgacgatgacaaggagcttcggtcctaccaatggga-3', RV LGP2: 5'-tcagtccagggagaggtccga-3'). PCR products were then introduced into the pcDNA3.1 TOPO plasmid (Life Technologies, Foster City, CA) to generate the 3xFLAG LGP2 expression constructs. For production of the recombinant LGP2 protein, the 3xFLAG-human LGP2 sequence was amplified using the forward primer 5'-actcgagttatggactacaagaccatgacggg-3' and the reverse primer 5'-ttgcggcccctcagtcaggagaggtccga-3' and cloned into the XhoI and NotI sites of the pBacPAK-His3-GST plasmid. Recombinant 3xFLAG LGP2 was expressed as a GST-tagged protein in SF9 insect cells using a baculovirus expression system and purified on a single step by affinity chromatography using Glutathione Sepharose matrix (GE Healthcare Life Sciences, Buckinghamshire, UK). The 3xFLAG LGP2 was eluted by GST tag cleavage using in-house 3C enzymatic digestion. A final polishing step was then performed on a superdex 200 10/300 GL column (GE Healthcare). Protein purity was then verified on an acrylamide gel and the protein yield was quantified using a Nanodrop apparatus (ThermoScientific, Wilmington, DE).

The M2 (Sigma) and IgG1 isotype match control (BD Pharmingen, San Diego, CA) antibodies were used for immunoprecipitation. M2 antibody was used at 1/5000 dilution for Western blot. Anti-mouse HRP antibody (Southern Biotech, Birmingham, AL) was used at 1/10,000 dilution for Western blot. IFN α /D (PBL Assay Science) was used at 100 units/ml for 24 hr to pre-treat cells. Ribavirin powder (Sigma) was reconstituted in DMSO and used at 4 mM final concentration.

Cells

HeLa, BHK21, and Vero cells were from Cancer Research UK (CRUK) Cell services. HEK293 selected for responsiveness to RLR agonists were previously described (**Pichlmair et al., 2009**). WT, *Ifih1*^{-/-}, *Ifih1*^{+/-}, *Ddx58*^{-/-}, *Ddx58*^{+/-}, *Ddx58*^{-/+}, *Dhx58*^{-/-} and *Dhx58*^{+/-}, MEFs were generated as previously described (**Kato et al., 2006**), immortalised with simian virus 40 large T antigen and selected on puromycin (final concentration, 2 mg/ml) for 2 weeks. HeLa and BHK21 cells were grown in 10% FCS-containing minimum essential medium (CRUK) or Glasgow media (Life Technologies), respectively. All other cell lines were grown in Dulbecco's modified Eagle's medium containing 10% FCS and 2 mM glutamine. Mouse BM-DCs were generated using GM-CSF as described previously (**Inaba et al., 1992**). Briefly, femur and tibia were collected from both hindquarters. Bones were flushed with RPMI 1640 (Life Technologies) media containing 10% FCS, 100U/ml Penicillin/Streptomycin, 5 μ M β -mercaptoethanol and 200 units/ml of GM-CSF (CRUK) and passed through a 70 μ m cell strainer. Cells were then cultured for 5 days with medium renewal every 2 days.

Viruses

Influenza A virus (IAV) (PR8 strain) and EMCV were as previously described (**Pichlmair et al. 2009**). EMCV Zn_{c19AC22A}, EMCV Δ L and EMCV L_{FMDV} (mengovirus strain), were produced as described (**Feng et al., 2012**). Other EMCV mutants were generated as follows: pEC9 EMCV WT, pEC9 EMCV Δ L, pEC9 EMCV Δ L_{ac} and pEC9 EMCV Δ L_{zn} plasmids (kind gift from Ann C Palmenberg) were in vitro transcribed to generate full length EMCV RNA using T7 Megascript kit (Ambion) as per manufacturer's

instructions. Products were then digested with DNase I and purified with phenol:chloroform:isoamylalcohol (25:24:1), followed by chloroform extraction and ethanol precipitation. RNAs were transfected into HeLa cells to generate viruses, which were subsequently amplified on BHK21 cell monolayers until cytopathic effects were observed. Cell lysates were then freeze-thawed three times, cleared and centrifuged for 2 hr at 22,000 rpm (SW 32 Ti Rotor, Beckman ultracentrifuge) at 4°C on 20% sucrose cushion to purify viral particles. The pelleted viral particles were resuspended in 10 mM Tris pH7, 2 mM MgCl₂ containing buffer and viral content quantified by plaque assay on Vero cells.

Mouse infection

IFNAR1 KO mice were obtained from Michel Aguet (University of Lausanne) and backcrossed 14 times to C57BL/6J. The mice were bred at CRUK or at St Mary's Hospital (kind gift from Cecilia Johansson) in specific-pathogen free conditions. For infection, 10- to 12-week-old C57BL/6-IFNAR1 KO mice were injected intraperitoneally with 10⁶ pfu of the indicated virus in 200 µl of PBS. Control mice were injected with 200 µl of PBS. Serum and organs were collected from culled animals 24 hr after injection. All animal experiments were performed in accordance with national and institutional guidelines for animal care and were approved by the London Research Institute Animal Ethics Committee and by the UK Home Office (project licence PPL 80/2309).

RNAs

The IVT RNA used as a positive control for IFN induction was the IVT neomycin sequence previously described (*Rehwinkel et al., 2010*). The in vitro transcribed RNA derived from the L AS and sense RNA sequence were generated by in vitro transcription using the T3 and Sp6 Megascript kit (Ambion Life Technologies) using the PCR with primer fw 5'-gcgactctctcatttga-3' and rv 5'-aaatttagtgacacatagaagcgtcctgaaaacgacttccatgt-3' or fw 5'-aaaattaaccctcactaaaggaggagaacttgcgacactctctcac-3' and rv 5'-tcgaaaacgacttccatgtct-3' for the production of the L AS and sense templates.

Viral genomic RNAs were extracted from purified viral suspension using Trizol LS reagent (Life Technologies) as per manufacturer's recommendations. For RNA extracted from infected HeLa cells, HeLa cells were infected with EMCV or IAV at an MOI of 1 for 16 hr before total RNA was extracted using Trizol. For separation of RNA into ss and dsRNA fractions, ssRNAs were first precipitated in presence of 2M LiCl. Double-stranded RNAs were then ethanol precipitated from the supernatant in presence of 0.7M LiCl. RNA pellets were washed with 70% ethanol, dried, and resuspended in RNase free water.

Calf intestinal phosphatase (New England Biolabs, Ipswich, MA), Terminator (Epicenter Biotechnologies, Madison, WI), RNaseT1 (Ambion Life Technologies), Polyphosphatase (Epicenter Biotechnologies), RNase A (Sigma, St. Louis, MO) and RNase III (Ambion Life Technologies) were used as per manufacturer's recommendations. A control reaction omitting the enzyme was carried out in parallel. RNA was recovered by extraction with phenol:chloroform:isoamylalcohol (25:24:1), followed by chloroform extraction and precipitation with ethanol and sodium acetate in the presence of glycogen (Ambion). All RNAs were quantified using a Nanodrop apparatus.

For quantitative RT-PCR analysis of *Ifnb1*, *Ifit1*, *IFNB1*, *gapdh*, *GAPDH*, *VP1* and *L* genes, RNA was extracted from 1 × 10⁵ MEFs, BM-DCs or HeLa cells using the RNeasy kit (Qiagen, Valencia, CA) or from infected mouse organs using Trizol.

Construction of the NS L AS influenza segment and vRNP reconstitution assay

To generate the NS L AS Influenza segment, we amplified the L EMCV fragment amplified using the forward primer 5'-aaaccatggatggccacaaccatggaac-3' and the reverse primer 5'-aaaccatggctgtaactc-gaaaacgactt-3' and introduced it into NcoI site of the pPoll_NS plasmid encoding the NS segment sequence of Influenza WSN strain (gift from Ervin Fodor). vRNP were then reconstituted in HEK 293T cells as previously described in *Rehwinkel et al. (2010)*.

Quantitative RT-PCR analysis

RNA was treated with DNase I (Qiagen) prior to reverse transcription using superscript II reverse transcription reagents (Life Technologies) according to the manufacturer's instructions. PCR was performed with TaqMan Universal PCR master Mix (Applied Biosystem Life Technologies) and the following taqman reagent assays: mouse *Ifit1* ID Mm00515153_m1, mouse *Ifnb1* ID Mm00439546_s1, mouse *gapdh* ID 4308313, human *IFNB1* ID Hs02621180_s1, human *gapdh* ID 402869. To detect viral RNA, Express Syber GreenER reagent (Life Technologies) was used in combination with the following

primers: fw 5'-gcgcaactctcacttttga-3' and rv 5'-tcgaaaacgacttccatgtct-3' for detection of the L region or fw 5'-cctcttccccccttgggt-3' and rv 5'-caggctccggcactataaac-3' for detection of the VP1 region. Data were normalized to levels of gapdh.

For strand-specific detection of viral RNA, RNA was first reverse transcribed using Superscript II (Life Technologies) in the presence of primers specific for L antisense (5'-ggccgcatggtggcgaataagcgcaactctcacttttga-3') or VP1 antisense (5'-ggccgcatggtggcgaataaacaggtccggcactataaac-3'). cDNAs were then subjected to Exonuclease I (New England Biolabs) treatment and purified using Qiaquick PCR purification kit (Qiagen). In the next step, quantitative RT-PCR was performed in presence of Express Syber GreenER (Invitrogen) using the following primers: common forward primer 5'-aataatcataagccgcatggtggcgaataa-3' in combination with either L reverse primer 5'-aataatcataatcgaaaacgacttccatgtct-3' or 1D reverse primer 5'-aataatcataaccttctcccccttgggt-3' to detect L or 1D region respectively. RNA levels were calculated by comparison with a dilution curve of cDNA from EMCV-infected cells.

Detection of IFN stimulatory activity

IFN- β luciferase reporter assay: 2.5×10^5 of HEK293 cells or IFN-A/D treated MEFs were transfected with 200 ng of p125Luc (gift from T Fujita, Kyoto university, Japan) and 50 ng pRL-TK (Promega, Madison, WI) using Lipofectamine 2000 (Life Technologies) as per manufacturer's instructions. Cells were incubated for 6–8 hr and were then transfected with water (mock control) or with test or control RNAs using lipofectamine. Luciferase activity was analysed in cell lysates 12 to 16 hr later using the Dual luciferase reporter Assay system (Promega). In all cases, firefly luciferase values were divided by Renilla luciferase values to normalise for transfection efficiency. All data are shown as fold increase relative to reporter cells transfected with water alone.

MEF assay: MEFs were pre-treated with 100 units/ml of IFN-A/D (PBL interferon) for 24 hr and plated into 24-well plates at 0.5×10^5 cell/well. The cells were then transfected with test or control RNAs using lipofectamine. After overnight culture, mIFN- α was measured in cell supernatants by ELISA as described previously (Rehwinkel et al., 2010) or MEF RNA was extracted with an RNeasy kit (Qiagen) following manufacturer's instructions for RT-PCR analysis of Ifit1 and Ifnb1 induction.

HeLa assay: HeLa cells were pre-treated with 100 units/ml of IFN-A/D (PBL Assay Science) for 24 hr and plated into 24-well plates at 0.5×10^5 cell/well. The cells were then transfected with the indicated amounts of test or control RNAs using lipofectamine. After overnight culture, HeLa RNA was extracted for RT-PCR analysis of IFNB1 induction.

LGP2 immunoprecipitation

Around 10–15 million HeLa cells were transfected with 30 μ g of 3xFLAG LGP2 IP plasmids using lipofectamine reagent following the manufacturer instructions. The cells were incubated for 16 hr, lipofectamine was washed away and the cells were incubated in fresh medium for 6–8 hr. HeLa cells expressing the 3xFLAG constructs were then infected with EMCV at an MOI of 1 for 16 hr. The cells were subsequently washed and lysed in lysis buffer (10 mM Tris pH 7.4, 2.5 mM MgCl₂, 200 mM NaCl, 0.5% NP40, 1X protease inhibitor cocktail [Roche, Mannheim, Germany], 0.5 U/ml RNasin [Promega]). Lysate was incubated for 30 min on ice, cleared by centrifugation for 10 min and the supernatant was collected. At this stage a small fraction of the input was collected for protein and RNA extraction. 5 μ g of M2-anti-FLAG (Sigma) or IgG1 isotype control antibody was added to 500 μ l of lysate and incubated on a rotating shaker for 1 hr at 4°C. 300 μ l of washed Gamma Bind Plus Sepharose Beads (GE Healthcare Bioscience AB) were then added to the mixture for another 1 hr. The beads were then precipitated by centrifugation and washed four times with 1 ml of lysis buffer. The beads were then split into two samples for protein or RNA extraction. Proteins were extracted from Protein/RNA complexes by boiling the beads for 5 min in SDS sample buffer for Western blot analysis. RNAs were purified from the beads by Phenol/chloroform extraction followed by ethanol precipitation. RNA was then quantified using a Nanodrop apparatus and the same amount of RNA from each sample was tested for IFN stimulatory activity as indicated.

For the IP using recombinant LGP2, 5 μ g of the purified protein was incubated with 20 μ g of total EMCV-infected RNA (MOI 1; 16 hr) in lysis buffer for 1 hr at 4°C on a rotating shaker. The rest of the IP was performed the same way as for the LGP2 IP from infected cells.

Deep sequencing of RNA

Input material pooled from five replicate cultures was subjected to immunoprecipitation with anti-FLAG or control IgG1 antibody (see above). RNA extracted from 10 independent IPs was pooled

and ribosomal RNA was removed using Ribo-Zero rRNA Removal Kit (Human.Mouse.Rat) (Epicenter RZH1046, Madison, WI) according to the manufacturer's protocol. After ribosomal RNA removal, the RNA was tested for its ability to activate the IFN- β promoter luciferase reporter. The RNA was then prepared for Illumina sequencing using an optimised version of the original Directional mRNA-Seq Library Prep protocol (Pre-Release Protocol Rev.A). The original protocol was optimised from 1 μ g of total RNA input to a total input of up to 173 ng. Reagents supplied by Illumina included 10 \times v1.5 sRNA 3' Adaptor; SRA 5' Adaptor; SRA RT primer; PCR Primer GX1/GX2. The remaining reagents recommended on the protocol were outsourced from alternative vendors. To analyse both coding and non-coding RNA regions, the poly(A) purification step was omitted. After fragmentation of the total RNA (optimised incubation of 2 min at 80°C), the RNA was checked for efficient fragmentation sizing, ribosomal RNA contamination and RIN using the Agilent 2100 Bioanalyzer QC Pico RNA chip. After library preparation, the PCR reaction was optimised by replacing the recommended PCR polymerase with Kapa Hifi DNA Polymerase (KAPA Biosystems, Wilmington, MA) in addition to optimising the number of PCR cycles from 12 to 18 cycles using the recommended PCR cycling conditions. The final library preparation was then size selected at 150 bp–450 bp using a 2% Agarose E-gel (Invitrogen) to remove unwanted regions in excess of 500 bp which was detected using the Agilent 2100 Bioanalyzer QC DNA 1000 chip. Next generation sequencing and library preparation was performed in the Advanced Sequencing Facility (ASF) at the London Research Institute on the Genome Analyzer Ix (GAIIx) with a single-end 72 bp sequencing run alongside a PhiX control of 1–5% in every lane of the flowcell. Sequencing typically generated ~30 million 60 bp single-end reads.

Alignment to the EMCV strain pEC9 genome (genbank accession ID DQ288856) was performed using Bowtie ([Langmead et al., 2009](#); version 0.12.7) permitting a maximum of three mismatches per read. Genome-wide coverage was calculated using the genomeCoverageBed function in BEDTools ([Quinlan and Hall, 2010](#); version 2.16.2) and all subsequent plots were generated using the statistical programming language, R (R core team 2012, R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; version 2.15). To generate more comparable data across samples the number of reads were normalised to the number of reads per million.

Statistical analysis

An unpaired two-tailed Student's *t* test was used to determine statistically significant differences. *p* values of less than 0.05 were considered statistically significant. GraphPad Prism version 6 for Macintosh (GraphPad Software) was used for statistical analysis of data.

Acknowledgements

We thank Ann C Palmenberg, Takashi Fujita, Ervin Fodor, Shizuo Akira and Cecilia Johansson for generous gifts of reagents and mice. We thank Cecilia Johansson, Barbara U Schraml and Kathryn Snelgrove for reading the manuscript, Mike Skinner for advice and all members of the Immunobiology laboratory for helpful discussions and comments. SD is a recipient of Cancer Research UK and Marie-Curie long-term fellowships (FP7-PEOPLE-2010-IEF-273483). CRS is funded by Cancer Research UK, a prize from Fondation Bettencourt-Schueller, and a grant from the European Research Council (ERC Advanced Researcher Grant AdG-2010-268670). QF is supported by Mosaic grant (NWO-017.006.043) and FJM by Echo grant (NWO-CW-700.59.007) from the Netherlands Organisation for Scientific Research (NWO).

Additional information

Funding

Funder	Grant reference number	Author
Cancer Research UK	N/A	Safia Deddouche, Delphine Goubau, Jan Rehwinkel, Probir Chakravarty, Sharmin Begum, Pierre V Maillard, Annabel Borg, Nik Matthews, Caetano Reis e Sousa

Funder	Grant reference number	Author
Medical Research Council		Jan Rehwinkel
Marie Curie		Safia Deddouche
Fondation Bettencourt-Schueller	N/A	Caetano Reis e Sousa
European Research Council	AdG-2010-268670	Caetano Reis e Sousa
Netherlands Organisation for Scientific Research - Mosaic grant	NWO-017.006.043	Qian Feng
Netherlands Organisation for Scientific Research - ECHO Grant	NWO-CW-700.59.007	Frank J M van Kuppeveld

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

SD, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article; DG, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article; JR, Contributed unpublished essential data or reagents; PC, Analysis and interpretation of data; SB, NM, Acquisition of data; PVM, QF, FJMK, Analysis and interpretation of data, Contributed unpublished essential data or reagents; AB, Provided reagents, Conception and design; CRS, Conception and design, Analysis and interpretation of data, Drafting or revising the article

Ethics

Animal experimentation: All animal experiments were performed in accordance with national and institutional guidelines for animal care and were approved by the London Research Institute Animal Ethics Committee and by the UK Home Office (project licence PPL 80/2309).

Additional files

Major dataset

The following previously published dataset was used:

Author(s)	Year	Dataset title	Dataset ID and/or URL	Database, license, and accessibility information
Martin LR, Neal ZC, McBride MS, Palmenberg AC, Aminev A, Hill M, Groppo R	2000, 2005	Encephalomyococ virus strain pEC9, complete genome	DQ288856.1; http://www.ncbi.nlm.nih.gov/nuccore/DQ288856.1	Publicly available at NCBI GenBank (http://www.ncbi.nlm.nih.gov/genbank/).

References

- Baum A**, García-Sastre A. 2010. Induction of type I interferon by RNA viruses: cellular receptors and their substrates. *Amino Acids* **38**:1283–1299. doi: [10.1007/s00726-009-0374-0](https://doi.org/10.1007/s00726-009-0374-0).
- Baum A**, Sachidanandam R, García-Sastre A. 2010. Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. *Proceedings of the National Academy of Sciences of the United States of America* **107**:16303–16308. doi: [10.1073/pnas.1005077107](https://doi.org/10.1073/pnas.1005077107).
- Berke IC**, Modis Y. 2012. MDA5 cooperatively forms dimers and ATP-sensitive filaments upon binding double-stranded RNA. *The EMBO Journal* **31**:1714–1726. doi: [10.1038/emboj.2012.19](https://doi.org/10.1038/emboj.2012.19).
- Berke IC**, Yu X, Modis Y, Egelman EH. 2012. MDA5 assembles into a polar helical filament on dsRNA. *Proceedings of the National Academy of Sciences of the United States of America* **109**:18437–18441. doi: [10.1073/pnas.1212186109](https://doi.org/10.1073/pnas.1212186109).
- Borghese F**, Michiels T. 2011. The leader protein of cardiomyoviruses inhibits stress granule assembly. *Journal of Virology* **85**:9614–9622. doi: [10.1128/JVI.00480-11](https://doi.org/10.1128/JVI.00480-11).
- Bruns AM**, Pollpeter D, Hadizadeh N, Myong S, Marko JF, Horvath CM. 2012. ATP Hydrolysis enhances RNA recognition and antiviral signal transduction by the innate immune sensor, laboratory of genetics and physiology 2 (LGP2). *The Journal of Biological Chemistry* **288**:938–946. doi: [10.1074/jbc.M112.424416](https://doi.org/10.1074/jbc.M112.424416).

- Childs KS**, Randall RE, Goodbourn S. 2013. LGP2 plays a critical role in sensitizing Mda-5 to activation by double-stranded RNA. *PLOS ONE* **8**:e64202. doi: [10.1371/journal.pone.0064202](https://doi.org/10.1371/journal.pone.0064202).
- Diebold SS**, Montoya M, Unger H, Alexopoulou L, Roy P, Haswell LE, Al-Shamkhani A, Flavell R, Borrow P, Reis e Sousa C. 2003. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. *Nature* **424**:324–328. doi: [10.1038/nature01783](https://doi.org/10.1038/nature01783).
- Dvorak CM**, Hall DJ, Hill M, Riddle M, Pranter A, Dillman J, Deibel M, Palmenberg AC. 2001. Leader protein of encephalomyocarditis virus binds zinc, is phosphorylated during viral infection, and affects the efficiency of genome translation. *Virology* **290**:261–271. doi: [10.1006/viro.2001.1193](https://doi.org/10.1006/viro.2001.1193).
- Feng Q**, Hato SV, Langereis MA, Zoll J, Virgen-Slane R, Peisley A, Hur S, Semler BL, van Rij RP, van Kuppeveld FJM. 2012. MDA5 detects the double-stranded RNA replicative form in picornavirus-infected cells. *Cell Reports* **2**:1187–1196. doi: [10.1016/j.celrep.2012.10.005](https://doi.org/10.1016/j.celrep.2012.10.005).
- Funk A**, Truong K, Nagasaki T, Torres S, Floden N, Balmori Melian E, Edmonds J, Dong H, Shi P-Y, Khromykh AA. 2010. RNA structures required for production of subgenomic flavivirus RNA. *Journal of Virology* **84**:11407–11417. doi: [10.1128/JVI.01159-10](https://doi.org/10.1128/JVI.01159-10).
- Goubau D**, Deddouche S, Reis e Sousa C. 2013. Cytosolic sensing of viruses. *Immunity* **38**:855–869. doi: [10.1016/j.immuni.2013.05.007](https://doi.org/10.1016/j.immuni.2013.05.007).
- Grandvaux N**, Servant MJ, tenOever B, Sen GC, Balachandran S, Barber GN, Lin R, Hiscott J. 2002. Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. *Journal of Virology* **76**:5532–5539. doi: [10.1128/JVI.76.11.5532-5539.2002](https://doi.org/10.1128/JVI.76.11.5532-5539.2002).
- Haller O**, Kochs G, Weber F. 2007. Interferon, Mx, and viral countermeasures. *Cytokine & Growth Factor Reviews* **18**:425–433. doi: [10.1016/j.cytogfr.2007.06.001](https://doi.org/10.1016/j.cytogfr.2007.06.001).
- Hato SV**, Ricour C, Schulte BM, Lanke KHW, de Bruijn M, Zoll J, Melchers WJG, Michiels T, van Kuppeveld FJM. 2007. The mengovirus leader protein blocks interferon- α /beta gene transcription and inhibits activation of interferon regulatory factor 3. *Cellular Microbiology* **9**:2921–2930. doi: [10.1111/j.1462-5822.2007.01006.x](https://doi.org/10.1111/j.1462-5822.2007.01006.x).
- Hornung V**, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann K-K, Schlee M, Endres S, Hartmann G. 2006. 5'-Triphosphate RNA is the ligand for RIG-I. *Science* **314**:994–997. doi: [10.1126/science.1132505](https://doi.org/10.1126/science.1132505).
- Inaba K**, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *The Journal of Experimental Medicine* **176**:1693–1702. doi: [10.1084/jem.176.6.1693](https://doi.org/10.1084/jem.176.6.1693).
- Kato H**, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K, Hiiragi A, Dermody TS, Fujita T, Akira S. 2008. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-1 and melanoma differentiation-associated gene 5. *The Journal of Experimental Medicine* **205**:1601–1610. doi: [10.1084/jem.20080091](https://doi.org/10.1084/jem.20080091).
- Kato H**, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, Akira S. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* **441**:101–105. doi: [10.1038/nature04734](https://doi.org/10.1038/nature04734).
- Langereis MA**, Feng Q, van Kuppeveld FJ. 2013. MDA5 localizes to stress granules, but this localization is not required for the induction of type I interferon. *Journal of Virology* **87**:6314–6325. doi: [10.1128/JVI.03213-12](https://doi.org/10.1128/JVI.03213-12).
- Langmead B**, Trapnell C, Pop M, Salzberg SL. 2009. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biology* **10**:R25. doi: [10.1186/gb-2009-10-3-r25](https://doi.org/10.1186/gb-2009-10-3-r25).
- Luthra P**, Sun D, Silverman RH, He B. 2011. Activation of IFN- β expression by a viral mRNA through RNase L and MDA5. *Proceedings of the National Academy of Sciences of the United States of America* **108**:2118–2123. doi: [10.1073/pnas.1012409108](https://doi.org/10.1073/pnas.1012409108).
- Malathi K**, Dong B, Gale M, Silverman RH. 2007. Small self-RNA generated by RNase L amplifies antiviral innate immunity. *Nature* **448**:816–819. doi: [10.1038/nature06042](https://doi.org/10.1038/nature06042).
- Malathi K**, Saito T, Crochet N, Barton DJ, Gale M, Silverman RH. 2010. RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP. *RNA* **16**:2108–2119. doi: [10.1261/rna.2244210](https://doi.org/10.1261/rna.2244210).
- Onomoto K**, Jogi M, Yoo J-S, Narita R, Morimoto S, Takemura A, Sambhara S, Kawaguchi A, Osari S, Nagata K, Matsumiya T, Namiki H, Yoneyama M, Fujita T. 2012. Critical role of an antiviral stress granule containing RIG-I and PKR in viral detection and innate immunity. *PLOS ONE* **7**:e43031. doi: [10.1371/journal.pone.0043031](https://doi.org/10.1371/journal.pone.0043031).
- Peisley A**, Jo MH, Lin C, Wu B, Orme-Johnson M, Walz T, Hohng S, Hur S. 2012. Kinetic mechanism for viral dsRNA length discrimination by MDA5 filaments. *Proceedings of the National Academy of Sciences of the United States of America* **109**:E3340–E3349. doi: [10.1073/pnas.1208618109](https://doi.org/10.1073/pnas.1208618109).
- Peisley A**, Lin C, Wu B, Orme-Johnson M, Liu M, Walz T, Hur S. 2011. Cooperative assembly and dynamic disassembly of MDA5 filaments for viral dsRNA recognition. *Proceedings of the National Academy of Sciences of the United States of America* **108**:21010–21015. doi: [10.1073/pnas.1113651108](https://doi.org/10.1073/pnas.1113651108).
- Pichlmair A**, Schulz O, Tan CP, Näslund TI, Liljeström P, Weber F, Reis e Sousa C. 2006. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. *Science* **314**:997–1001. doi: [10.1126/science.1132998](https://doi.org/10.1126/science.1132998).
- Pichlmair A**, Schulz O, Tan CP, Rehwinkel J, Kato H, Takeuchi O, Akira S, Way M, Schiavo G, Reis e Sousa C. 2009. Activation of MDA5 requires higher-order RNA structures generated during virus infection. *Journal of Virology* **83**:10761–10769. doi: [10.1128/JVI.00770-09](https://doi.org/10.1128/JVI.00770-09).
- Quinlan AR**, Hall IM. 2010. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**:841–842. doi: [10.1093/bioinformatics/btq033](https://doi.org/10.1093/bioinformatics/btq033).

- Rehwinkel J**, Tan CP, Goubau D, Schulz O, Pichlmair A, Bier K, Robb N, Vreede F, Barclay W, Fodor E, Reis e Sousa C. 2010. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. *Cell* **140**:397–408. doi: [10.1016/j.cell.2010.01.020](https://doi.org/10.1016/j.cell.2010.01.020).
- Sato H**, Kato H, Kumagai Y, Yoneyama M, Sato S, Matsushita K, Tsujimura T, Fujita T, Akira S, Takeuchi O. 2010. LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. *Proceedings of the National Academy of Sciences of the United States of America* **107**:1512–1517. doi: [10.1073/pnas.0912986107](https://doi.org/10.1073/pnas.0912986107).
- Schlee M**, Roth A, Hornung V, Hagmann CA, Wimmenauer V, Barchet W, Coch C, Janke M, Mihailovic A, Wardle G, Juraneck S, Kato H, Kawai T, Poeck H, Fitzgerald KA, Takeuchi O, Akira S, Tuschl T, Latz E, Ludwig J, Hartmann G. 2009. Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. *Immunity* **31**:25–34. doi: [10.1016/j.immuni.2009.05.008](https://doi.org/10.1016/j.immuni.2009.05.008).
- Schmidt A**, Schwerdt T, Hamm W, Hellmuth JC, Cui S, Wenzel M, Hoffmann FS, Michallet M-C, Besch R, Hopfner K-P, Endres S, Rothenfusser S. 2009. 5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. *Proceedings of the National Academy of Sciences of the United States of America* **106**:12067–12072. doi: [10.1073/pnas.0900971106](https://doi.org/10.1073/pnas.0900971106).
- Schoggins JW**, Rice CM. 2011. Interferon-stimulated genes and their antiviral effector functions. *Current Opinion in Virology* **1**:519–525. doi: [10.1016/j.coviro.2011.10.008](https://doi.org/10.1016/j.coviro.2011.10.008).
- Stetson DB**, Medzhitov R. 2006. Type I interferons in host defense. *Immunity* **25**:373–381. doi: [10.1016/j.immuni.2006.08.007](https://doi.org/10.1016/j.immuni.2006.08.007).
- Takaoka A**, Yanai H. 2006. Interferon signalling network in innate defence. *Cellular Microbiology* **8**:907–922. doi: [10.1111/j.1462-5822.2006.00716.x](https://doi.org/10.1111/j.1462-5822.2006.00716.x).
- Triantafilou K**, Vakakis E, Kar S, Richer E, Evans GL, Triantafilou M. 2012. Visualisation of direct interaction of MDA5 and the dsRNA replicative intermediate form of positive strand RNA viruses. *Journal of Cell Science* **125**:4761–4769. doi: [10.1242/jcs.103887](https://doi.org/10.1242/jcs.103887).
- Tuthill TJ**, Gropelli E, Hogle JM, Rowlands DJ. 2010. Picornaviruses. *Current Topics in Microbiology and Immunology* **343**:43–89. doi: [10.1007/82_2010_37](https://doi.org/10.1007/82_2010_37).
- Venkataraman T**, Valdes M, Elsby R, Kakuta S, Caceres G, Saijo S, Iwakura Y, Barber GN. 2007. Loss of DExD/H box RNA helicase LGP2 manifests disparate antiviral responses. *Journal of Immunology* **178**:6444–6455.
- Weber M**, Gawanbacht A, Habjan M, Rang A, Borner C, Schmidt AM, Veitinger S, Jacob R, Devignot S, Kochs G, Garcia-Sastre A, Weber F. 2013. Incoming RNA virus nucleocapsids containing a 5'-triphosphorylated genome activate RIG-I and antiviral signaling. *Cell Host and Microbe* **13**:336–346. doi: [10.1016/j.chom.2013.01.012](https://doi.org/10.1016/j.chom.2013.01.012).
- Wu B**, Peisley A, Richards C, Yao H, Zeng X, Lin C, Chu F, Walz T, Hur S. 2012. Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5. *Cell* **152**:276–289. doi: [10.1016/j.cell.2012.11.048](https://doi.org/10.1016/j.cell.2012.11.048).
- Züst R**, Cervantes-Barragan L, Habjan M, Maier R, Neuman BW, Ziebuhr J, Szretter KJ, Baker SC, Barchet W, Diamond MS, Siddell SG, Ludwig B, Thiel V. 2011. Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. *Nature Immunology* **12**:137–143. doi: [10.1038/ni.1979](https://doi.org/10.1038/ni.1979).